{
  "test_run_id": "test_run_2025-12-15_22-04-14",
  "timestamp": "2025-12-15T22:04:14.403589",
  "configuration": {
    "api_base_url": "https://gemini-chatbot-480267397633.us-central1.run.app",
    "num_tests": 50,
    "parallel": 5,
    "timeout": 120,
    "save_reports": true,
    "report_dir": "automated_testing/reports"
  },
  "summary": {
    "total_tests": 10,
    "passed": 0,
    "failed": 10,
    "pass_rate": 0.0,
    "average_overall_score": 53.4,
    "average_response_time": 18.64900210729409
  },
  "metrics": {
    "crash_prevention": {
      "average_score": 70.0,
      "passed": 7,
      "failed": 3
    },
    "eligibility_accuracy": {
      "average_score": 0.0,
      "passed": 0,
      "failed": 10
    },
    "conversation_quality": {
      "average_score": 77.0,
      "passed": 8,
      "failed": 2
    },
    "edge_case_handling": {
      "average_score": 100.0,
      "applicable_tests": 2,
      "passed": 10
    },
    "performance": {
      "average_response_time": 18.64900210729409,
      "passed": 6
    }
  },
  "failure_summary": {
    "total_failures": 34,
    "by_type": {
      "crash": 6,
      "eligibility_logic_error": 10,
      "conversation_quality_issue": 14,
      "performance_issue": 4
    }
  },
  "failures": [
    {
      "test_id": "AUTO_TEST_targeted_psoriasis_003",
      "patient_profile": {
        "age": 41,
        "conditions": [
          "Plaque Psoriasis"
        ],
        "medications": [
          "Topical Corticosteroids"
        ]
      },
      "type": "crash",
      "error_type": "timeout",
      "error_message": "Unknown error",
      "likely_location": "aiohttp timeout in conversation_simulator.py or slow Gemini API response",
      "severity": "critical"
    },
    {
      "test_id": "AUTO_TEST_targeted_psoriasis_003",
      "patient_profile": {
        "age": 41,
        "conditions": [
          "Plaque Psoriasis"
        ],
        "medications": [
          "Topical Corticosteroids"
        ]
      },
      "type": "crash",
      "error_type": "conversation_failure",
      "error_message": "",
      "likely_location": "Unknown - check full error trace",
      "severity": "critical"
    },
    {
      "test_id": "AUTO_TEST_targeted_psoriasis_003",
      "patient_profile": {
        "age": 41,
        "conditions": [
          "Plaque Psoriasis"
        ],
        "medications": [
          "Topical Corticosteroids"
        ]
      },
      "type": "eligibility_logic_error",
      "reason": "Prescreening flow did not complete",
      "final_state": "failed",
      "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py",
      "severity": "high"
    },
    {
      "test_id": "AUTO_TEST_targeted_psoriasis_003",
      "patient_profile": {
        "age": 41,
        "conditions": [
          "Plaque Psoriasis"
        ],
        "medications": [
          "Topical Corticosteroids"
        ]
      },
      "type": "conversation_quality_issue",
      "issue": "Too few questions asked (0, expected at least 4)",
      "severity": "medium",
      "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
    },
    {
      "test_id": "AUTO_TEST_targeted_psoriasis_003",
      "patient_profile": {
        "age": 41,
        "conditions": [
          "Plaque Psoriasis"
        ],
        "medications": [
          "Topical Corticosteroids"
        ]
      },
      "type": "performance_issue",
      "avg_response_time": 20.36611306667328,
      "max_response_time": 24.83254098892212,
      "severity": "low",
      "recommendation": "Investigate slow API responses or Gemini API delays"
    },
    {
      "test_id": "AUTO_TEST_edge_multimorbid_000",
      "patient_profile": {
        "age": 71,
        "conditions": [
          "Rheumatoid Arthritis",
          "Psoriasis",
          "Alzheimers",
          "Gout"
        ],
        "medications": [
          "Memantine",
          "Cyclosporine",
          "Febuxostat",
          "Rivastigmine",
          "Allopurinol",
          "Galantamine",
          "Prednisone",
          "Biologics (Humira)"
        ]
      },
      "type": "eligibility_logic_error",
      "reason": "No eligibility determination found in conversation",
      "likely_location": "core/prescreening/gemini_prescreening_manager.py:evaluate_eligibility()",
      "severity": "high"
    },
    {
      "test_id": "AUTO_TEST_targeted_gout_002",
      "patient_profile": {
        "age": 34,
        "conditions": [
          "Gout",
          "Hypertension"
        ],
        "medications": [
          "Lisinopril"
        ]
      },
      "type": "eligibility_logic_error",
      "reason": "No eligibility determination found in conversation",
      "likely_location": "core/prescreening/gemini_prescreening_manager.py:evaluate_eligibility()",
      "severity": "high"
    },
    {
      "test_id": "AUTO_TEST_random_000",
      "patient_profile": {
        "age": 62,
        "conditions": [
          "Alzheimers"
        ],
        "medications": [
          "Galantamine",
          "Memantine"
        ]
      },
      "type": "eligibility_logic_error",
      "reason": "No eligibility determination found in conversation",
      "likely_location": "core/prescreening/gemini_prescreening_manager.py:evaluate_eligibility()",
      "severity": "high"
    },
    {
      "test_id": "AUTO_TEST_targeted_psoriasis_000",
      "patient_profile": {
        "age": 31,
        "conditions": [
          "Plaque Psoriasis"
        ],
        "medications": [
          "Topical Corticosteroids"
        ]
      },
      "type": "crash",
      "error_type": "timeout",
      "error_message": "Unknown error",
      "likely_location": "aiohttp timeout in conversation_simulator.py or slow Gemini API response",
      "severity": "critical"
    },
    {
      "test_id": "AUTO_TEST_targeted_psoriasis_000",
      "patient_profile": {
        "age": 31,
        "conditions": [
          "Plaque Psoriasis"
        ],
        "medications": [
          "Topical Corticosteroids"
        ]
      },
      "type": "crash",
      "error_type": "conversation_failure",
      "error_message": "",
      "likely_location": "Unknown - check full error trace",
      "severity": "critical"
    },
    {
      "test_id": "AUTO_TEST_targeted_psoriasis_000",
      "patient_profile": {
        "age": 31,
        "conditions": [
          "Plaque Psoriasis"
        ],
        "medications": [
          "Topical Corticosteroids"
        ]
      },
      "type": "eligibility_logic_error",
      "reason": "Prescreening flow did not complete",
      "final_state": "failed",
      "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py",
      "severity": "high"
    },
    {
      "test_id": "AUTO_TEST_targeted_psoriasis_000",
      "patient_profile": {
        "age": 31,
        "conditions": [
          "Plaque Psoriasis"
        ],
        "medications": [
          "Topical Corticosteroids"
        ]
      },
      "type": "conversation_quality_issue",
      "issue": "Too few questions asked (0, expected at least 4)",
      "severity": "medium",
      "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
    },
    {
      "test_id": "AUTO_TEST_targeted_psoriasis_000",
      "patient_profile": {
        "age": 31,
        "conditions": [
          "Plaque Psoriasis"
        ],
        "medications": [
          "Topical Corticosteroids"
        ]
      },
      "type": "conversation_quality_issue",
      "issue": "Repeated question: I couldn't find any trials for Psoriasis in Jackso...",
      "severity": "medium",
      "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
    },
    {
      "test_id": "AUTO_TEST_targeted_psoriasis_000",
      "patient_profile": {
        "age": 31,
        "conditions": [
          "Plaque Psoriasis"
        ],
        "medications": [
          "Topical Corticosteroids"
        ]
      },
      "type": "conversation_quality_issue",
      "issue": "Repeated question: I couldn't find any trials for Psoriasis in Jackso...",
      "severity": "medium",
      "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
    },
    {
      "test_id": "AUTO_TEST_targeted_psoriasis_000",
      "patient_profile": {
        "age": 31,
        "conditions": [
          "Plaque Psoriasis"
        ],
        "medications": [
          "Topical Corticosteroids"
        ]
      },
      "type": "conversation_quality_issue",
      "issue": "Repeated question: I couldn't find any trials for Psoriasis in Jackso...",
      "severity": "medium",
      "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
    },
    {
      "test_id": "AUTO_TEST_targeted_psoriasis_000",
      "patient_profile": {
        "age": 31,
        "conditions": [
          "Plaque Psoriasis"
        ],
        "medications": [
          "Topical Corticosteroids"
        ]
      },
      "type": "conversation_quality_issue",
      "issue": "Repeated question: I couldn't find any trials for Psoriasis in Jackso...",
      "severity": "medium",
      "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
    },
    {
      "test_id": "AUTO_TEST_targeted_psoriasis_000",
      "patient_profile": {
        "age": 31,
        "conditions": [
          "Plaque Psoriasis"
        ],
        "medications": [
          "Topical Corticosteroids"
        ]
      },
      "type": "conversation_quality_issue",
      "issue": "Repeated question: I couldn't find any trials for Psoriasis in Jackso...",
      "severity": "medium",
      "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
    },
    {
      "test_id": "AUTO_TEST_targeted_psoriasis_000",
      "patient_profile": {
        "age": 31,
        "conditions": [
          "Plaque Psoriasis"
        ],
        "medications": [
          "Topical Corticosteroids"
        ]
      },
      "type": "performance_issue",
      "avg_response_time": 20.456628019159492,
      "max_response_time": 26.84646701812744,
      "severity": "low",
      "recommendation": "Investigate slow API responses or Gemini API delays"
    },
    {
      "test_id": "AUTO_TEST_targeted_psoriasis_001",
      "patient_profile": {
        "age": 39,
        "conditions": [
          "Plaque Psoriasis"
        ],
        "medications": [
          "Topical Corticosteroids"
        ]
      },
      "type": "eligibility_logic_error",
      "reason": "No eligibility determination found in conversation",
      "likely_location": "core/prescreening/gemini_prescreening_manager.py:evaluate_eligibility()",
      "severity": "high"
    },
    {
      "test_id": "AUTO_TEST_random_002",
      "patient_profile": {
        "age": 70,
        "conditions": [
          "Alzheimers",
          "Sleep Disorders"
        ],
        "medications": [
          "Donepezil",
          "Memantine"
        ]
      },
      "type": "eligibility_logic_error",
      "reason": "No eligibility determination found in conversation",
      "likely_location": "core/prescreening/gemini_prescreening_manager.py:evaluate_eligibility()",
      "severity": "high"
    },
    {
      "test_id": "AUTO_TEST_random_003",
      "patient_profile": {
        "age": 53,
        "conditions": [
          "Psoriasis",
          "Cardiovascular Disease",
          "Depression"
        ],
        "medications": [
          "Topical Corticosteroids",
          "Methotrexate",
          "Cyclosporine"
        ]
      },
      "type": "eligibility_logic_error",
      "reason": "No eligibility determination found in conversation",
      "likely_location": "core/prescreening/gemini_prescreening_manager.py:evaluate_eligibility()",
      "severity": "high"
    },
    {
      "test_id": "AUTO_TEST_random_003",
      "patient_profile": {
        "age": 53,
        "conditions": [
          "Psoriasis",
          "Cardiovascular Disease",
          "Depression"
        ],
        "medications": [
          "Topical Corticosteroids",
          "Methotrexate",
          "Cyclosporine"
        ]
      },
      "type": "performance_issue",
      "avg_response_time": 20.130237738291424,
      "max_response_time": 21.23750615119934,
      "severity": "low",
      "recommendation": "Investigate slow API responses or Gemini API delays"
    },
    {
      "test_id": "AUTO_TEST_edge_multimorbid_001",
      "patient_profile": {
        "age": 69,
        "conditions": [
          "Psoriasis",
          "Copd",
          "Gout",
          "Alzheimers",
          "Diabetes",
          "Hypertension"
        ],
        "medications": [
          "Insulin",
          "Febuxostat",
          "Symbicort",
          "Galantamine",
          "Biologics (Humira)"
        ]
      },
      "type": "eligibility_logic_error",
      "reason": "No eligibility determination found in conversation",
      "likely_location": "core/prescreening/gemini_prescreening_manager.py:evaluate_eligibility()",
      "severity": "high"
    },
    {
      "test_id": "AUTO_TEST_edge_multimorbid_001",
      "patient_profile": {
        "age": 69,
        "conditions": [
          "Psoriasis",
          "Copd",
          "Gout",
          "Alzheimers",
          "Diabetes",
          "Hypertension"
        ],
        "medications": [
          "Insulin",
          "Febuxostat",
          "Symbicort",
          "Galantamine",
          "Biologics (Humira)"
        ]
      },
      "type": "conversation_quality_issue",
      "issue": "Too few questions asked (4, expected at least 5)",
      "severity": "medium",
      "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
    },
    {
      "test_id": "AUTO_TEST_random_001",
      "patient_profile": {
        "age": 45,
        "conditions": [
          "Copd"
        ],
        "medications": [
          "Albuterol",
          "Symbicort"
        ]
      },
      "type": "crash",
      "error_type": "timeout",
      "error_message": "Unknown error",
      "likely_location": "aiohttp timeout in conversation_simulator.py or slow Gemini API response",
      "severity": "critical"
    },
    {
      "test_id": "AUTO_TEST_random_001",
      "patient_profile": {
        "age": 45,
        "conditions": [
          "Copd"
        ],
        "medications": [
          "Albuterol",
          "Symbicort"
        ]
      },
      "type": "crash",
      "error_type": "conversation_failure",
      "error_message": "",
      "likely_location": "Unknown - check full error trace",
      "severity": "critical"
    },
    {
      "test_id": "AUTO_TEST_random_001",
      "patient_profile": {
        "age": 45,
        "conditions": [
          "Copd"
        ],
        "medications": [
          "Albuterol",
          "Symbicort"
        ]
      },
      "type": "eligibility_logic_error",
      "reason": "Prescreening flow did not complete",
      "final_state": "failed",
      "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py",
      "severity": "high"
    },
    {
      "test_id": "AUTO_TEST_random_001",
      "patient_profile": {
        "age": 45,
        "conditions": [
          "Copd"
        ],
        "medications": [
          "Albuterol",
          "Symbicort"
        ]
      },
      "type": "conversation_quality_issue",
      "issue": "Too few questions asked (0, expected at least 4)",
      "severity": "medium",
      "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
    },
    {
      "test_id": "AUTO_TEST_random_001",
      "patient_profile": {
        "age": 45,
        "conditions": [
          "Copd"
        ],
        "medications": [
          "Albuterol",
          "Symbicort"
        ]
      },
      "type": "conversation_quality_issue",
      "issue": "Repeated question: I couldn't find any trials for Copd in Birmingham,...",
      "severity": "medium",
      "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
    },
    {
      "test_id": "AUTO_TEST_random_001",
      "patient_profile": {
        "age": 45,
        "conditions": [
          "Copd"
        ],
        "medications": [
          "Albuterol",
          "Symbicort"
        ]
      },
      "type": "conversation_quality_issue",
      "issue": "Repeated question: I couldn't find any trials for Copd in Birmingham,...",
      "severity": "medium",
      "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
    },
    {
      "test_id": "AUTO_TEST_random_001",
      "patient_profile": {
        "age": 45,
        "conditions": [
          "Copd"
        ],
        "medications": [
          "Albuterol",
          "Symbicort"
        ]
      },
      "type": "conversation_quality_issue",
      "issue": "Repeated question: I couldn't find any trials for Copd in Birmingham,...",
      "severity": "medium",
      "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
    },
    {
      "test_id": "AUTO_TEST_random_001",
      "patient_profile": {
        "age": 45,
        "conditions": [
          "Copd"
        ],
        "medications": [
          "Albuterol",
          "Symbicort"
        ]
      },
      "type": "conversation_quality_issue",
      "issue": "Repeated question: I couldn't find any trials for Copd in Birmingham,...",
      "severity": "medium",
      "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
    },
    {
      "test_id": "AUTO_TEST_random_001",
      "patient_profile": {
        "age": 45,
        "conditions": [
          "Copd"
        ],
        "medications": [
          "Albuterol",
          "Symbicort"
        ]
      },
      "type": "conversation_quality_issue",
      "issue": "Repeated question: I couldn't find any trials for Copd in Birmingham,...",
      "severity": "medium",
      "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
    },
    {
      "test_id": "AUTO_TEST_random_001",
      "patient_profile": {
        "age": 45,
        "conditions": [
          "Copd"
        ],
        "medications": [
          "Albuterol",
          "Symbicort"
        ]
      },
      "type": "performance_issue",
      "avg_response_time": 20.052853294781276,
      "max_response_time": 24.73931574821472,
      "severity": "low",
      "recommendation": "Investigate slow API responses or Gemini API delays"
    }
  ],
  "detailed_results": [
    {
      "patient_id": "AUTO_TEST_targeted_psoriasis_003",
      "patient_profile": {
        "patient_id": "AUTO_TEST_targeted_psoriasis_003",
        "profile_type": "targeted",
        "demographics": {
          "age": 41,
          "gender": "male",
          "location": "Jackson, MS",
          "name": "Test Psoriasis Patient",
          "first_name": "Test",
          "last_name": "Patient"
        },
        "medical_history": {
          "primary_condition": "Psoriasis",
          "conditions": [
            "Plaque Psoriasis"
          ],
          "medications": [
            "Topical Corticosteroids"
          ],
          "duration_years": 5,
          "pasi_score": 15,
          "body_surface_area": "20%"
        },
        "expected_behavior": {
          "should_find_trials": true,
          "likely_eligible": true,
          "expected_question_count_range": [
            4,
            7
          ],
          "target_trial_keywords": [
            "psoriasis",
            "dermatology"
          ]
        }
      },
      "conversation_result": {
        "session_id": "AUTO_TEST_targeted_psoriasis_003",
        "patient_id": "AUTO_TEST_targeted_psoriasis_003",
        "conversation_log": [
          {
            "user_message": "Psoriasis trials in Jackson, MS",
            "bot_response": "I couldn't find any trials for Psoriasis in Jackson, MS at the moment. Would you like to try a different condition or location?",
            "metadata": {
              "session_id": "AUTO_TEST_targeted_psoriasis_003",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "search_trials",
              "entities_collected": {
                "condition": "Psoriasis",
                "location": "Jackson",
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "search_trials",
                "parameters": {
                  "condition": "Psoriasis",
                  "location": "Jackson, MS"
                },
                "response_text": "Of course, happy to look in a new area for you. Searching for Psoriasis clinical trials near Jackson, Mississippi now. One moment...",
                "new_state": "trials_shown",
                "collect_entities": [],
                "metadata": {
                  "reasoning": "The user has provided a new location ('Jackson, MS') for their existing condition ('Psoriasis'). The current state is 'trials_shown' from a previous search, but this new request overrides it. The most appropriate action is to perform a new search with the updated location information to directly fulfill the user's request."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "no_trials_found": true,
              "condition": "Psoriasis",
              "location": "Jackson, MS"
            },
            "response_time": 15.899685144424438,
            "timestamp": "2025-12-15T21:52:50.739501"
          },
          {
            "user_message": "Yes, check my eligibility",
            "bot_response": "I understand you'd like to check your eligibility. It looks like we didn't find any Psoriasis trials in the Jackson area in our last search. Before we can check eligibility, we first need to find a specific trial.\n\nWould you like me to try searching again with a wider radius, or perhaps look for any remote trials you could participate in from home?",
            "metadata": {
              "session_id": "AUTO_TEST_targeted_psoriasis_003",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "general_response",
              "entities_collected": {
                "condition": null,
                "location": null,
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": true,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "general_response",
                "parameters": {},
                "response_text": "I understand you'd like to check your eligibility. It looks like we didn't find any Psoriasis trials in the Jackson area in our last search. Before we can check eligibility, we first need to find a specific trial.\n\nWould you like me to try searching again with a wider radius, or perhaps look for any remote trials you could participate in from home?",
                "new_state": "awaiting_search_confirmation",
                "collect_entities": [
                  "boolean_answer",
                  "search_scope"
                ],
                "metadata": {
                  "reasoning": "The user wants to start an eligibility check, but the context (as inferred from the OpenAI reasoning) indicates that no trials were found in the previous step. It's impossible to start a prescreening without a specific trial. Therefore, the best action is to explain the situation empathetically and offer a constructive next step, such as broadening the search. This manages the user's expectation and helps them move forward toward their goal."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "general_response": true
            },
            "response_time": 24.83254098892212,
            "timestamp": "2025-12-15T21:53:15.572282"
          }
        ],
        "final_state": "failed",
        "total_turns": 2,
        "total_questions_asked": 0,
        "errors": [
          {
            "type": "timeout",
            "message": "I'm not sure, can you clarify?",
            "response_time": 30.83907198905945
          },
          {
            "type": "conversation_failure",
            "error": "",
            "state": "prescreening_active",
            "timestamp": "2025-12-15T21:53:46.412206"
          }
        ]
      },
      "validation": {
        "passed": false,
        "overall_score": 26.0,
        "crash_prevention": {
          "passed": false,
          "score": 0.0,
          "error_count": 2,
          "errors": [
            {
              "type": "timeout",
              "message": "I'm not sure, can you clarify?",
              "response_time": 30.83907198905945
            },
            {
              "type": "conversation_failure",
              "error": "",
              "state": "prescreening_active",
              "timestamp": "2025-12-15T21:53:46.412206"
            }
          ],
          "failures": [
            {
              "type": "crash",
              "error_type": "timeout",
              "error_message": "Unknown error",
              "likely_location": "aiohttp timeout in conversation_simulator.py or slow Gemini API response",
              "severity": "critical"
            },
            {
              "type": "crash",
              "error_type": "conversation_failure",
              "error_message": "",
              "likely_location": "Unknown - check full error trace",
              "severity": "critical"
            }
          ]
        },
        "eligibility_accuracy": {
          "passed": false,
          "score": 0.0,
          "reason": "Prescreening did not complete",
          "failures": [
            {
              "type": "eligibility_logic_error",
              "reason": "Prescreening flow did not complete",
              "final_state": "failed",
              "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py",
              "severity": "high"
            }
          ]
        },
        "conversation_quality": {
          "passed": true,
          "score": 80.0,
          "total_questions_asked": 0,
          "issues": [
            "Too few questions asked (0, expected at least 4)"
          ],
          "failures": [
            {
              "type": "conversation_quality_issue",
              "issue": "Too few questions asked (0, expected at least 4)",
              "severity": "medium",
              "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
            }
          ]
        },
        "edge_case_handling": {
          "passed": true,
          "score": 100.0,
          "applicable": false,
          "failures": []
        },
        "performance": {
          "passed": false,
          "score": 40.0,
          "avg_response_time": 20.36611306667328,
          "max_response_time": 24.83254098892212,
          "status": "slow",
          "failures": [
            {
              "type": "performance_issue",
              "avg_response_time": 20.36611306667328,
              "max_response_time": 24.83254098892212,
              "severity": "low",
              "recommendation": "Investigate slow API responses or Gemini API delays"
            }
          ]
        },
        "failure_points": [
          {
            "type": "crash",
            "error_type": "timeout",
            "error_message": "Unknown error",
            "likely_location": "aiohttp timeout in conversation_simulator.py or slow Gemini API response",
            "severity": "critical"
          },
          {
            "type": "crash",
            "error_type": "conversation_failure",
            "error_message": "",
            "likely_location": "Unknown - check full error trace",
            "severity": "critical"
          },
          {
            "type": "eligibility_logic_error",
            "reason": "Prescreening flow did not complete",
            "final_state": "failed",
            "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py",
            "severity": "high"
          },
          {
            "type": "conversation_quality_issue",
            "issue": "Too few questions asked (0, expected at least 4)",
            "severity": "medium",
            "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
          },
          {
            "type": "performance_issue",
            "avg_response_time": 20.36611306667328,
            "max_response_time": 24.83254098892212,
            "severity": "low",
            "recommendation": "Investigate slow API responses or Gemini API delays"
          }
        ],
        "recommendations": [
          "\ud83d\udea8 CRITICAL: Fix crashes and exceptions. Review error logs and add error handling.",
          "\u26a0\ufe0f HIGH: Review eligibility evaluation logic in gemini_prescreening_manager.py",
          "\u2139\ufe0f LOW: Slow response times. Optimize API calls or consider caching."
        ]
      },
      "timestamp": "2025-12-15T21:53:46.412346"
    },
    {
      "patient_id": "AUTO_TEST_edge_multimorbid_000",
      "patient_profile": {
        "patient_id": "AUTO_TEST_edge_multimorbid_000",
        "profile_type": "edge_case",
        "demographics": {
          "age": 71,
          "gender": "male",
          "location": "New Orleans, LA",
          "name": "Multi Condition Patient",
          "first_name": "Multi",
          "last_name": "Patient"
        },
        "medical_history": {
          "primary_condition": "Rheumatoid Arthritis",
          "conditions": [
            "Rheumatoid Arthritis",
            "Psoriasis",
            "Alzheimers",
            "Gout"
          ],
          "medications": [
            "Memantine",
            "Cyclosporine",
            "Febuxostat",
            "Rivastigmine",
            "Allopurinol",
            "Galantamine",
            "Prednisone",
            "Biologics (Humira)"
          ],
          "duration_years": 10
        },
        "expected_behavior": {
          "should_find_trials": true,
          "likely_eligible": false,
          "expected_question_count_range": [
            5,
            10
          ],
          "edge_case_type": "multi_morbidity"
        }
      },
      "conversation_result": {
        "session_id": "AUTO_TEST_edge_multimorbid_000",
        "patient_id": "AUTO_TEST_edge_multimorbid_000",
        "conversation_log": [
          {
            "user_message": "Rheumatoid Arthritis trials in New Orleans, LA",
            "bot_response": "Great! I found 5 clinical trial(s) available in New Orleans, LA:\n\n**Dr. Patrick Dennis**\n  \u2022 Osteoarthritis of the Knee (1 trial)\n  \u2022 Gout (2 trials)\n  \u2022 COVID-19 (1 trial)\n\n**Dr. Lesley Saketkoo**\n  \u2022 Systemic Sclerosis (1 trial)\n\nWould you like to:\n1. Check your eligibility for any of these trials?\n2. Learn more about a specific condition?\n3. See trials in a different location?",
            "metadata": {
              "session_id": "AUTO_TEST_edge_multimorbid_000",
              "current_state": "trials_shown",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "search_trials",
              "entities_collected": {
                "condition": "Rheumatoid Arthritis",
                "location": "New Orleans",
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "search_trials",
                "parameters": {
                  "condition": "Rheumatoid Arthritis",
                  "location": "New Orleans, LA"
                },
                "response_text": "Of course, I can certainly help you look for trials for Rheumatoid Arthritis in New Orleans. Let me see what I can find for you.",
                "new_state": "trials_shown",
                "collect_entities": [],
                "metadata": {
                  "reasoning": "The user has provided a new condition ('Rheumatoid Arthritis') and a new location ('New Orleans, LA'), clearly indicating a new search request. This is a context switch from the previous search for Psoriasis. Since all the necessary information for a new search is available, the `search_trials` action is the most appropriate next step. The response acknowledges the user's new request and confirms the search parameters before proceeding."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "trials_found": 5,
              "condition": "Rheumatoid Arthritis",
              "location": "New Orleans, LA",
              "trials_data": [
                {
                  "id": 53,
                  "trial_name": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of VENT-02 in Adult Participants with Painful Knee Osteoarthritis and Obesity",
                  "conditions": "Osteoarthritis of the Knee",
                  "description": "This is a Phase 2 research study, meaning it's still in the early stages of testing a new drug called VENT-02.  The study is randomized, which means participants are assigned to different treatment groups by chance, like flipping a coin. It's also double-blind, so neither the participants nor the researchers know who is getting the actual drug or a placebo (an inactive substance).  Ventus Therapeutics U.S., Inc. is sponsoring the study, which will take place at about 40 centers across the United States. The study is expected to last approximately one year, from Q3 2025 to Q2 2026.\n\nThis study is looking for adults aged 45 to 80 who have painful knee osteoarthritis and obesity (BMI \u2265 30 kg/m\u00b2).  You must have had knee pain for a certain duration and severity, and your knee will be examined with an X-ray to confirm the osteoarthritis.  Women of childbearing potential must agree to use highly effective birth control.  You will not be able to participate if you have certain other health conditions like inflammatory arthritis, have recently had knee surgery or injections, are taking certain medications, or have had significant recent weight changes.  If you qualify and choose to participate, you'll be asked to visit the study center regularly for assessments and follow-up.\n\nDuring the study, you will receive either VENT-02 at different doses or a placebo, taken orally twice a day for 84 days.  Researchers will track your knee pain using a questionnaire called the WOMAC, as well as your body weight.  They will also monitor your overall health, including checking your vital signs, doing blood tests, and performing electrocardiograms (ECGs).  The main goals are to see if VENT-02 reduces knee pain and helps with weight loss.  The study will also assess the safety of VENT-02 and how it's processed by the body.  You will have follow-up visits for a week after your last dose.",
                  "investigator_name": "Dr. Patrick Dennis",
                  "site_location": "New Orleans, LA",
                  "protocol_summary": "This is a Phase 2 research study, meaning it's still in the early stages of testing a new drug called VENT-02.  The study is randomized, which means participants are assigned to different treatment groups by chance, like flipping a coin. It's also double-blind, so neither the participants nor the researchers know who is getting the actual drug or a placebo (an inactive substance).  Ventus Therapeutics U.S., Inc. is sponsoring the study, which will take place at about 40 centers across the United States. The study is expected to last approximately one year, from Q3 2025 to Q2 2026.\n\nThis study is looking for adults aged 45 to 80 who have painful knee osteoarthritis and obesity (BMI \u2265 30 kg/m\u00b2).  You must have had knee pain for a certain duration and severity, and your knee will be examined with an X-ray to confirm the osteoarthritis.  Women of childbearing potential must agree to use highly effective birth control.  You will not be able to participate if you have certain other health conditions like inflammatory arthritis, have recently had knee surgery or injections, are taking certain medications, or have had significant recent weight changes.  If you qualify and choose to participate, you'll be asked to visit the study center regularly for assessments and follow-up.\n\nDuring the study, you will receive either VENT-02 at different doses or a placebo, taken orally twice a day for 84 days.  Researchers will track your knee pain using a questionnaire called the WOMAC, as well as your body weight.  They will also monitor your overall health, including checking your vital signs, doing blood tests, and performing electrocardiograms (ECGs).  The main goals are to see if VENT-02 reduces knee pain and helps with weight loss.  The study will also assess the safety of VENT-02 and how it's processed by the body.  You will have follow-up visits for a week after your last dose.",
                  "total_sites": 1,
                  "similarity_score": 0.7637404232767281
                },
                {
                  "id": 2,
                  "trial_name": "A Phase 3 Randomized, Double-blind, Multi-center, Placebo-controlled Study to Evaluate the Efficacy and Safety of AR882 in Participants with Gout",
                  "conditions": "Gout",
                  "description": "",
                  "investigator_name": "Dr. Patrick Dennis",
                  "site_location": "New Orleans, LA",
                  "protocol_summary": "The clinical trial, identified as Protocol AR882-301, is a Phase 3, randomized, double-blind, multi-center, placebo-controlled study designed to evaluate the efficacy and safety of the investigational drug AR882 in participants with gout. Sponsored by Arthrosi Therapeutics, Inc., this trial will be conducted across approximately 100 sites in the United States and Canada. The primary objective is to assess the ability of AR882 to reduce serum uric acid (sUA) levels in participants, with a specific focus on achieving sUA levels below 6.0 mg/dL by Month 6.\n\nParticipants in the trial will be randomly assigned to receive either AR882 or a placebo. The study will be double-blind, meaning neither the participants nor the investigators will know which treatment each participant is receiving. The intervention involves the administration of AR882, with the primary aim of evaluating its efficacy in lowering sUA levels and reducing tophus burden. The CAPER method will be employed to assess the response of target tophi, with evaluations conducted at Months 6 and 12 to determine the presence of disease progression.\n\nThe primary endpoint of the study is the proportion of participants achieving sUA levels below 6.0 mg/dL at Month 6. Secondary endpoints include the reduction of tophus burden and the maintenance of sUA levels below 6.0 mg/dL at Months 9 and 12, alongside the absence of gout flares over a three-month period. The trial will last until all participants have completed 12 months or have discontinued. Notable inclusion criteria include a diagnosis of gout and baseline tophi, while exclusion criteria may involve other significant health conditions that could interfere with the study's outcomes.",
                  "total_sites": 17,
                  "similarity_score": 0.7600697008909448
                },
                {
                  "id": 69,
                  "trial_name": "A Randomized, Double-Blinded, Placebo-Controlled, Phase 2, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Adult Participants With Systemic Sclerosis",
                  "conditions": "Systemic Sclerosis",
                  "description": "This is a Phase 2 research study, meaning it's one of the early stages of testing a new medicine.  The study is randomized, which means participants are assigned to different treatment groups by chance, like flipping a coin. It's also double-blinded, so neither the participants nor the doctors know who is getting the study drug or the placebo (an inactive substance).  This study is sponsored by argenx BV and will be conducted at multiple locations (multi-center). The study will last approximately 15 months for each participant. \n\nThis study is looking for adults with systemic sclerosis (SSc).  To be eligible, you'll need to meet specific criteria, including having a confirmed diagnosis of SSc. Some reasons you might not be able to participate include having certain other medical conditions or being pregnant.  During the study, you can expect regular visits to the study site for assessments and treatment.  The researchers are aiming to include a diverse group of participants, but there may be limits on the number of people without interstitial lung disease (ILD). \n\nIn this study, you will receive either efgartigimod PH20 SC, the study drug, or a placebo.  The study drug or placebo will be given as a weekly injection under the skin.  Researchers will be measuring several things, including changes in your skin thickness, how you're functioning in daily life, and your overall health.  The main goal is to see if efgartigimod PH20 SC improves skin sclerosis.  Other goals include assessing the safety of the drug, how it's processed by your body, and its effect on your immune system.  You'll have regular study visits, including baseline, weekly, and monthly assessments, for about a year, followed by a final safety check-up.",
                  "investigator_name": "Dr. Lesley Saketkoo",
                  "site_location": "New Orleans, LA",
                  "protocol_summary": "This is a Phase 2 research study, meaning it's one of the early stages of testing a new medicine.  The study is randomized, which means participants are assigned to different treatment groups by chance, like flipping a coin. It's also double-blinded, so neither the participants nor the doctors know who is getting the study drug or the placebo (an inactive substance).  This study is sponsored by argenx BV and will be conducted at multiple locations (multi-center). The study will last approximately 15 months for each participant. \n\nThis study is looking for adults with systemic sclerosis (SSc).  To be eligible, you'll need to meet specific criteria, including having a confirmed diagnosis of SSc. Some reasons you might not be able to participate include having certain other medical conditions or being pregnant.  During the study, you can expect regular visits to the study site for assessments and treatment.  The researchers are aiming to include a diverse group of participants, but there may be limits on the number of people without interstitial lung disease (ILD). \n\nIn this study, you will receive either efgartigimod PH20 SC, the study drug, or a placebo.  The study drug or placebo will be given as a weekly injection under the skin.  Researchers will be measuring several things, including changes in your skin thickness, how you're functioning in daily life, and your overall health.  The main goal is to see if efgartigimod PH20 SC improves skin sclerosis.  Other goals include assessing the safety of the drug, how it's processed by your body, and its effect on your immune system.  You'll have regular study visits, including baseline, weekly, and monthly assessments, for about a year, followed by a final safety check-up.",
                  "total_sites": 1,
                  "similarity_score": 0.7496248918983323
                }
              ],
              "semantic_search": true
            },
            "response_time": 23.7761390209198,
            "timestamp": "2025-12-15T21:52:58.621393"
          },
          {
            "user_message": "Yes, check my eligibility",
            "bot_response": "Great! I'll help you check your eligibility.\n\nI need to ask you a few questions about the rheumatoid arthritis trial.\n\n**Question 1 of 5:** What is your age?",
            "metadata": {
              "session_id": "AUTO_TEST_edge_multimorbid_000",
              "current_state": "prescreening_active",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "start_prescreening",
              "entities_collected": {
                "condition": null,
                "location": null,
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": "yes",
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "start_prescreening",
                "parameters": {},
                "response_text": "Great, I can help with that. I'll ask a few simple questions to see if you might be a match for these trials. This is just a preliminary check, and the final decision is always made by the study team.\n\nTo start, could you please tell me your age?",
                "new_state": "prescreening_started",
                "collect_entities": [
                  "age"
                ],
                "metadata": {
                  "reasoning": "The user has explicitly confirmed their desire to check eligibility ('Yes, check my eligibility') after being shown a list of trials (state: trials_shown). The most appropriate action is to begin the prescreening process. The response acknowledges their request, sets clear expectations about the preliminary nature of the check, and asks the first common eligibility question (age) to move the process forward. The state is updated to 'prescreening_started' to reflect this new phase of the conversation."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "prescreening_started": true,
              "trial_id": 53,
              "trial_name": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of VENT-02 in Adult Participants with Painful Knee Osteoarthritis and Obesity",
              "current_question_index": 0,
              "total_questions": 5,
              "current_question": "What is your age?",
              "expected_answer_type": "number"
            },
            "response_time": 17.282694101333618,
            "timestamp": "2025-12-15T21:53:15.904613"
          },
          {
            "user_message": "71",
            "bot_response": "I had trouble processing your answer. There seems to be an issue with the prescreening system. Please try searching for trials again.",
            "metadata": {
              "session_id": "AUTO_TEST_edge_multimorbid_000",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "continue_prescreening",
              "entities_collected": {
                "condition": null,
                "location": null,
                "age": 71,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "continue_prescreening",
                "parameters": {
                  "last_answer": {
                    "age": 71
                  }
                },
                "response_text": "Got it, thanks. Next question: How long have you been diagnosed with Rheumatoid Arthritis?",
                "new_state": "prescreening_active",
                "collect_entities": [
                  "duration"
                ],
                "metadata": {
                  "reasoning": "The user is in an active prescreening state and has provided their age in response to the previous question. The correct action is to continue the prescreening process by acknowledging their answer and asking the next logical question to determine their eligibility. The state remains 'prescreening_active' as we have not yet completed the questionnaire."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "prescreening_error": "failed_to_process_answer",
              "error_details": "'coroutine' object has no attribute 'criterion_id'",
              "error_type": "AttributeError"
            },
            "response_time": 13.753008127212524,
            "timestamp": "2025-12-15T21:53:29.657930"
          }
        ],
        "final_state": "completed",
        "total_turns": 3,
        "total_questions_asked": 5,
        "errors": [
          {
            "type": "unexpected_state",
            "bot_response": "I had trouble processing your answer. There seems to be an issue with the prescreening system. Please try searching for trials again."
          }
        ]
      },
      "validation": {
        "passed": false,
        "overall_score": 70.0,
        "crash_prevention": {
          "passed": true,
          "score": 100.0,
          "error_count": 0,
          "errors": [],
          "failures": []
        },
        "eligibility_accuracy": {
          "passed": false,
          "score": 0.0,
          "reason": "Could not extract eligibility result",
          "failures": [
            {
              "type": "eligibility_logic_error",
              "reason": "No eligibility determination found in conversation",
              "likely_location": "core/prescreening/gemini_prescreening_manager.py:evaluate_eligibility()",
              "severity": "high"
            }
          ]
        },
        "conversation_quality": {
          "passed": true,
          "score": 100.0,
          "total_questions_asked": 5,
          "issues": [],
          "failures": []
        },
        "edge_case_handling": {
          "passed": true,
          "score": 100.0,
          "applicable": true,
          "edge_case_type": "multi_morbidity",
          "completed": true,
          "failures": []
        },
        "performance": {
          "passed": true,
          "score": 70.0,
          "avg_response_time": 18.27061374982198,
          "max_response_time": 23.7761390209198,
          "status": "acceptable",
          "failures": []
        },
        "failure_points": [
          {
            "type": "eligibility_logic_error",
            "reason": "No eligibility determination found in conversation",
            "likely_location": "core/prescreening/gemini_prescreening_manager.py:evaluate_eligibility()",
            "severity": "high"
          }
        ],
        "recommendations": [
          "\u26a0\ufe0f HIGH: Review eligibility evaluation logic in gemini_prescreening_manager.py"
        ]
      },
      "timestamp": "2025-12-15T21:53:29.658723"
    },
    {
      "patient_id": "AUTO_TEST_targeted_gout_002",
      "patient_profile": {
        "patient_id": "AUTO_TEST_targeted_gout_002",
        "profile_type": "targeted",
        "demographics": {
          "age": 34,
          "gender": "male",
          "location": "Baton Rouge, LA",
          "name": "Test Gout Patient",
          "first_name": "Test",
          "last_name": "Patient"
        },
        "medical_history": {
          "primary_condition": "Gout",
          "conditions": [
            "Gout",
            "Hypertension"
          ],
          "medications": [
            "Lisinopril"
          ],
          "duration_years": 3,
          "flares_per_year": 4,
          "uric_acid_level": 8.5
        },
        "expected_behavior": {
          "should_find_trials": true,
          "likely_eligible": true,
          "expected_question_count_range": [
            5,
            8
          ],
          "target_trial_keywords": [
            "gout"
          ]
        }
      },
      "conversation_result": {
        "session_id": "AUTO_TEST_targeted_gout_002",
        "patient_id": "AUTO_TEST_targeted_gout_002",
        "conversation_log": [
          {
            "user_message": "Gout trials in Baton Rouge, LA",
            "bot_response": "Great! I found 5 clinical trial(s) available in Baton Rouge, LA:\n\n**Dr. Taylor Sanders**\n  \u2022 Gout (3 trials)\n  \u2022 Fibromyalgia (1 trial)\n\n**Dr. Ira Thorla**\n  \u2022 Female Pattern Hair Loss (Androgenetic Alopecia) (1 trial)\n\nWould you like to:\n1. Check your eligibility for any of these trials?\n2. Learn more about a specific condition?\n3. See trials in a different location?",
            "metadata": {
              "session_id": "AUTO_TEST_targeted_gout_002",
              "current_state": "trials_shown",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "search_trials",
              "entities_collected": {
                "condition": "Gout",
                "location": "Baton Rouge",
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "search_trials",
                "parameters": {
                  "condition": "Gout",
                  "location": "Baton Rouge, LA"
                },
                "response_text": "Of course. Let me check for Gout clinical trials in Baton Rouge, LA for you. One moment...",
                "new_state": "searching",
                "collect_entities": [],
                "metadata": {
                  "reasoning": "The user has provided both a condition ('Gout') and a new location ('Baton Rouge, LA'), fulfilling the requirements to perform a trial search. The previous search in Jackson, MS likely yielded no results, and the user is now following up with an alternative location. The `search_trials` action is the most direct way to help the user achieve their goal."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "trials_found": 5,
              "condition": "Gout",
              "location": "Baton Rouge, LA",
              "trials_data": [
                {
                  "id": 2,
                  "trial_name": "A Phase 3 Randomized, Double-blind, Multi-center, Placebo-controlled Study to Evaluate the Efficacy and Safety of AR882 in Participants with Gout",
                  "conditions": "Gout",
                  "description": "",
                  "investigator_name": "Dr. Taylor Sanders",
                  "site_location": "Baton Rouge, LA",
                  "protocol_summary": "The clinical trial, identified as Protocol AR882-301, is a Phase 3, randomized, double-blind, multi-center, placebo-controlled study designed to evaluate the efficacy and safety of the investigational drug AR882 in participants with gout. Sponsored by Arthrosi Therapeutics, Inc., this trial will be conducted across approximately 100 sites in the United States and Canada. The primary objective is to assess the ability of AR882 to reduce serum uric acid (sUA) levels in participants, with a specific focus on achieving sUA levels below 6.0 mg/dL by Month 6.\n\nParticipants in the trial will be randomly assigned to receive either AR882 or a placebo. The study will be double-blind, meaning neither the participants nor the investigators will know which treatment each participant is receiving. The intervention involves the administration of AR882, with the primary aim of evaluating its efficacy in lowering sUA levels and reducing tophus burden. The CAPER method will be employed to assess the response of target tophi, with evaluations conducted at Months 6 and 12 to determine the presence of disease progression.\n\nThe primary endpoint of the study is the proportion of participants achieving sUA levels below 6.0 mg/dL at Month 6. Secondary endpoints include the reduction of tophus burden and the maintenance of sUA levels below 6.0 mg/dL at Months 9 and 12, alongside the absence of gout flares over a three-month period. The trial will last until all participants have completed 12 months or have discontinued. Notable inclusion criteria include a diagnosis of gout and baseline tophi, while exclusion criteria may involve other significant health conditions that could interfere with the study's outcomes.",
                  "total_sites": 17,
                  "similarity_score": 0.8027487136996964
                },
                {
                  "id": 66,
                  "trial_name": "A Randomized, Double-blind, Multicenter, Colchicine and Placebo-controlled Study to Evaluate the Efficacy and Safety of ABP-745 in Subjects with an Acute Gout Flare",
                  "conditions": "Gout",
                  "description": "This is a Phase II, randomized, double-blind, placebo-controlled, multi-center study sponsored by Atom Therapeutics Co., Ltd.  The study will be conducted in the United States, Australia, and China and will last approximately 6 months for each participant, with the possibility of re-screening and continuing for another 6 months if no flare occurs in the initial period.  This means that neither you nor your doctor will know which treatment you are receiving, and participants will be randomly assigned to different treatment groups.  The study aims to determine how well ABP-745 works to treat acute gout flares compared to colchicine and a placebo.\n\nThis study is looking for men and women aged 18-70 with a BMI between 18 and 40 who have been diagnosed with gout and have experienced at least two gout flares in the past year.  You must be able to contact the study site and receive your first dose within 10 hours of a new flare starting, and you must be able to return to the site 24 hours after the first dose.  You will need to be able to attend several visits at the study site over a 7-day period during a flare and a final visit after treatment, as well as a safety follow-up phone call.  You may not be eligible to participate if you have certain other medical conditions or are taking certain medications.  Your doctor will discuss these criteria with you in more detail.\n\nParticipants will be randomly assigned to receive either ABP-745 (at one of two doses), colchicine, or a placebo.  The study will measure pain levels, tenderness, and swelling in your most affected joint.  The main goals are to see how much ABP-745 reduces pain at 24 hours after the first dose compared to colchicine and placebo.  Other measurements will include pain levels at later time points, the percentage of people who experience significant pain reduction, and how the treatment affects markers of inflammation in your blood.  You will take the study medication twice daily for 7 days during a flare.  You will have several visits to the study site during this time for assessments and blood draws.",
                  "investigator_name": "Dr. Taylor Sanders",
                  "site_location": "Baton Rouge, LA",
                  "protocol_summary": "This is a Phase II, randomized, double-blind, placebo-controlled, multi-center study sponsored by Atom Therapeutics Co., Ltd.  The study will be conducted in the United States, Australia, and China and will last approximately 6 months for each participant, with the possibility of re-screening and continuing for another 6 months if no flare occurs in the initial period.  This means that neither you nor your doctor will know which treatment you are receiving, and participants will be randomly assigned to different treatment groups.  The study aims to determine how well ABP-745 works to treat acute gout flares compared to colchicine and a placebo.\n\nThis study is looking for men and women aged 18-70 with a BMI between 18 and 40 who have been diagnosed with gout and have experienced at least two gout flares in the past year.  You must be able to contact the study site and receive your first dose within 10 hours of a new flare starting, and you must be able to return to the site 24 hours after the first dose.  You will need to be able to attend several visits at the study site over a 7-day period during a flare and a final visit after treatment, as well as a safety follow-up phone call.  You may not be eligible to participate if you have certain other medical conditions or are taking certain medications.  Your doctor will discuss these criteria with you in more detail.\n\nParticipants will be randomly assigned to receive either ABP-745 (at one of two doses), colchicine, or a placebo.  The study will measure pain levels, tenderness, and swelling in your most affected joint.  The main goals are to see how much ABP-745 reduces pain at 24 hours after the first dose compared to colchicine and placebo.  Other measurements will include pain levels at later time points, the percentage of people who experience significant pain reduction, and how the treatment affects markers of inflammation in your blood.  You will take the study medication twice daily for 7 days during a flare.  You will have several visits to the study site during this time for assessments and blood draws.",
                  "total_sites": 4,
                  "similarity_score": 0.7992400049183908
                },
                {
                  "id": 74,
                  "trial_name": "A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Dotinurad Compared With Allopurinol in Adult Participants With Hyperuricemia Associated With Gout",
                  "conditions": "Gout",
                  "description": "This is a Phase 3, randomized, double-blind, multicenter study sponsored by Crystalys Therapeutics, Inc.  The study will be conducted at up to 100 sites across North America and Europe and is expected to last approximately 2.5 years.  \"Double-blind\" means neither you nor your study doctor will know which medicine you are taking. \"Randomized\" means you will be assigned to a treatment group by chance, like flipping a coin.  This helps ensure the results are unbiased.\n\nThis study is for adults with gout who have experienced at least two gout flares in the past year and have been taking a stable dose of allopurinol (300-600mg daily, or 200mg for those with moderate kidney problems) for at least 3 months.  You must also have a serum uric acid (sUA) level of 6.5 mg/dL or higher at two screening visits.  You will not be able to participate if you have certain other medical conditions (these will be discussed during screening).  During the study, you will be asked to keep a diary of your medication intake, any gout flares you experience, and any related healthcare visits.  \n\nIn this study, you will receive either dotinurad (the investigational drug) or allopurinol.  Dotinurad will be given in increasing doses over the first 12 weeks.  Allopurinol will be given at the same dose you were taking before the study began.  The study will measure how well each medication lowers sUA levels in your blood, reduces the number of gout flares you experience, and assess any side effects.  The main goal is to see if dotinurad is as effective as allopurinol in lowering sUA at 24 weeks.  Other goals include evaluating the impact on gout flares and overall safety.  You will have regular check-ups every 2 weeks initially, then every 4 weeks, and will be asked to complete questionnaires about your health.  Even if you stop taking the study medication, you will be encouraged to continue with the follow-up visits.",
                  "investigator_name": "Dr. Taylor Sanders",
                  "site_location": "Baton Rouge, LA",
                  "protocol_summary": "This is a Phase 3, randomized, double-blind, multicenter study sponsored by Crystalys Therapeutics, Inc.  The study will be conducted at up to 100 sites across North America and Europe and is expected to last approximately 2.5 years.  \"Double-blind\" means neither you nor your study doctor will know which medicine you are taking. \"Randomized\" means you will be assigned to a treatment group by chance, like flipping a coin.  This helps ensure the results are unbiased.\n\nThis study is for adults with gout who have experienced at least two gout flares in the past year and have been taking a stable dose of allopurinol (300-600mg daily, or 200mg for those with moderate kidney problems) for at least 3 months.  You must also have a serum uric acid (sUA) level of 6.5 mg/dL or higher at two screening visits.  You will not be able to participate if you have certain other medical conditions (these will be discussed during screening).  During the study, you will be asked to keep a diary of your medication intake, any gout flares you experience, and any related healthcare visits.  \n\nIn this study, you will receive either dotinurad (the investigational drug) or allopurinol.  Dotinurad will be given in increasing doses over the first 12 weeks.  Allopurinol will be given at the same dose you were taking before the study began.  The study will measure how well each medication lowers sUA levels in your blood, reduces the number of gout flares you experience, and assess any side effects.  The main goal is to see if dotinurad is as effective as allopurinol in lowering sUA at 24 weeks.  Other goals include evaluating the impact on gout flares and overall safety.  You will have regular check-ups every 2 weeks initially, then every 4 weeks, and will be asked to complete questionnaires about your health.  Even if you stop taking the study medication, you will be encouraged to continue with the follow-up visits.",
                  "total_sites": 13,
                  "similarity_score": 0.7947402273735418
                }
              ],
              "semantic_search": true
            },
            "response_time": 21.13073205947876,
            "timestamp": "2025-12-15T21:52:55.978391"
          },
          {
            "user_message": "Yes, check my eligibility",
            "bot_response": "Great! I'll help you check your eligibility.\n\nI need to ask you a few questions about the gout trial.\n\n**Question 1 of 5:** What is your age?",
            "metadata": {
              "session_id": "AUTO_TEST_targeted_gout_002",
              "current_state": "prescreening_active",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "start_prescreening",
              "entities_collected": {
                "condition": null,
                "location": null,
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": "yes",
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "start_prescreening",
                "parameters": {},
                "response_text": "Great! Let's check your eligibility. To get started, could you please tell me which trial you're most interested in? You can refer to it by its number from the list I sent. I'll then ask you a few simple questions from the trial's official criteria.",
                "new_state": "awaiting_trial_selection",
                "collect_entities": [
                  "number",
                  "trial_name"
                ],
                "metadata": {
                  "reasoning": "The user has explicitly agreed to an eligibility check after being shown a list of trials. The current state is 'trials_shown'. The next logical step is to begin the prescreening process. Since the user didn't specify which trial, the response prompts them to select one from the list to begin the questionnaire. The state is updated to 'awaiting_trial_selection' to reflect this."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "prescreening_started": true,
              "trial_id": 2,
              "trial_name": "A Phase 3 Randomized, Double-blind, Multi-center, Placebo-controlled Study to Evaluate the Efficacy and Safety of AR882 in Participants with Gout",
              "current_question_index": 0,
              "total_questions": 5,
              "current_question": "What is your age?",
              "expected_answer_type": "number"
            },
            "response_time": 18.400137186050415,
            "timestamp": "2025-12-15T21:53:14.378781"
          },
          {
            "user_message": "34",
            "bot_response": "I had trouble processing your answer. There seems to be an issue with the prescreening system. Please try searching for trials again.",
            "metadata": {
              "session_id": "AUTO_TEST_targeted_gout_002",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "continue_prescreening",
              "entities_collected": {
                "condition": null,
                "location": null,
                "age": 34,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "continue_prescreening",
                "parameters": {},
                "response_text": "Great, thank you. Just a couple more questions. In the past 12 months, have you experienced two or more gout flares?",
                "new_state": "prescreening_active",
                "collect_entities": [
                  "boolean_answer"
                ],
                "metadata": {
                  "reasoning": "The user is in an active prescreening state and has provided their age. The next logical step is to continue with the prescreening process by asking another key eligibility question for Gout trials, such as the frequency of recent flares. The state remains 'prescreening_active' as the process is ongoing."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "prescreening_error": "failed_to_process_answer",
              "error_details": "'coroutine' object has no attribute 'criterion_id'",
              "error_type": "AttributeError"
            },
            "response_time": 14.462142944335938,
            "timestamp": "2025-12-15T21:53:28.841482"
          }
        ],
        "final_state": "completed",
        "total_turns": 3,
        "total_questions_asked": 5,
        "errors": [
          {
            "type": "unexpected_state",
            "bot_response": "I had trouble processing your answer. There seems to be an issue with the prescreening system. Please try searching for trials again."
          }
        ]
      },
      "validation": {
        "passed": false,
        "overall_score": 70.0,
        "crash_prevention": {
          "passed": true,
          "score": 100.0,
          "error_count": 0,
          "errors": [],
          "failures": []
        },
        "eligibility_accuracy": {
          "passed": false,
          "score": 0.0,
          "reason": "Could not extract eligibility result",
          "failures": [
            {
              "type": "eligibility_logic_error",
              "reason": "No eligibility determination found in conversation",
              "likely_location": "core/prescreening/gemini_prescreening_manager.py:evaluate_eligibility()",
              "severity": "high"
            }
          ]
        },
        "conversation_quality": {
          "passed": true,
          "score": 100.0,
          "total_questions_asked": 5,
          "issues": [],
          "failures": []
        },
        "edge_case_handling": {
          "passed": true,
          "score": 100.0,
          "applicable": false,
          "failures": []
        },
        "performance": {
          "passed": true,
          "score": 70.0,
          "avg_response_time": 17.997670729955036,
          "max_response_time": 21.13073205947876,
          "status": "acceptable",
          "failures": []
        },
        "failure_points": [
          {
            "type": "eligibility_logic_error",
            "reason": "No eligibility determination found in conversation",
            "likely_location": "core/prescreening/gemini_prescreening_manager.py:evaluate_eligibility()",
            "severity": "high"
          }
        ],
        "recommendations": [
          "\u26a0\ufe0f HIGH: Review eligibility evaluation logic in gemini_prescreening_manager.py"
        ]
      },
      "timestamp": "2025-12-15T21:53:28.842003"
    },
    {
      "patient_id": "AUTO_TEST_random_000",
      "patient_profile": {
        "patient_id": "AUTO_TEST_random_000",
        "profile_type": "random",
        "demographics": {
          "age": 62,
          "gender": "female",
          "location": "Charlotte, NC",
          "name": "Linda Brown",
          "first_name": "Linda",
          "last_name": "Brown"
        },
        "medical_history": {
          "primary_condition": "Alzheimers",
          "conditions": [
            "Alzheimers"
          ],
          "medications": [
            "Galantamine",
            "Memantine"
          ],
          "duration_years": 2
        },
        "expected_behavior": {
          "should_find_trials": true,
          "likely_eligible": true,
          "expected_question_count_range": [
            4,
            8
          ]
        }
      },
      "conversation_result": {
        "session_id": "AUTO_TEST_random_000",
        "patient_id": "AUTO_TEST_random_000",
        "conversation_log": [
          {
            "user_message": "Alzheimers trials in Charlotte, NC",
            "bot_response": "Great! I found 5 clinical trial(s) available in Charlotte, NC:\n\n**Dr. Keith Logan**\n  \u2022 Bipolar Depression (1 trial)\n\n**Dr. Melissa\tJones**\n  \u2022 COVID-19 (1 trial)\n  \u2022 Uncontrolled Hypertension (1 trial)\n  \u2022 Obesity (1 trial)\n  \u2022 Influenza Prevention (1 trial)\n\nWould you like to:\n1. Check your eligibility for any of these trials?\n2. Learn more about a specific condition?\n3. See trials in a different location?",
            "metadata": {
              "session_id": "AUTO_TEST_random_000",
              "current_state": "trials_shown",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "search_trials",
              "entities_collected": {
                "condition": "Alzheimers",
                "location": "Charlotte",
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "search_trials",
                "parameters": {
                  "condition": "Alzheimers",
                  "location": "Charlotte, NC"
                },
                "response_text": "Of course, I can help with that. It's important to explore all the options available. I'm now searching for Alzheimer's clinical trials in and around Charlotte, NC. I'll have a list for you in just a moment.",
                "new_state": "trials_found",
                "collect_entities": [],
                "metadata": {
                  "reasoning": "The user has provided a new condition ('Alzheimers') and a new location ('Charlotte, NC'), which is a clear context switch from the previous conversation about Psoriasis. Since both pieces of information required for a search are present, the most direct and helpful action is to perform the search. The response acknowledges the new request, confirms the search parameters, and sets expectations for the next step, maintaining a supportive tone."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "trials_found": 5,
              "condition": "Alzheimers",
              "location": "Charlotte, NC",
              "trials_data": [
                {
                  "id": 112,
                  "trial_name": "A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Investigational Product in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)",
                  "conditions": "Bipolar Depression",
                  "description": "This is a Phase 3 clinical research study for a new investigational product for bipolar depression. It is a global study taking place at multiple centers. The study is \"randomized\" and \"double-blind,\" which means you will be assigned by chance (like a coin flip) to receive either the investigational product or a placebo, a pill with no active medicine. Neither you nor your study doctor will know which treatment you are receiving, which helps ensure the results are unbiased. Your total participation in the study will last for approximately 18 weeks, which includes screening, a 6-week treatment period, and an 8-week follow-up period.\n\nThis study is looking for adults between the ages of 18 and 74 who have been diagnosed with Bipolar I or Bipolar II disorder and are currently experiencing a moderate to severe depressive episode. To be eligible, your current depressive episode must have lasted between 4 weeks and 12 months, and you must meet specific scores on depression rating scales. You may not be able to participate if you have recently had suicidal plans, have been found to be resistant to two or more previous treatments for your current episode, or are taking certain other psychiatric medications. The study team will review all eligibility criteria with you to determine if this study is a good fit.\n\nIf you join the study, you will take one capsule by mouth each day for 6 weeks; this will be either the investigational product or a placebo. The main purpose of the study is to see if the investigational product can reduce symptoms of depression more effectively than a placebo, which will be measured using a standard depression questionnaire (the MADRS). Researchers will also assess the product's effects on the loss of pleasure (anhedonia), its safety, and how quickly it may begin to work. Your participation will involve regular visits to the study center for assessments, which include questionnaires, vital signs checks, blood tests, and heart tracings (ECGs).",
                  "investigator_name": "Dr. Keith Logan",
                  "site_location": "Charlotte, NC",
                  "protocol_summary": "This is a Phase 3 clinical research study for a new investigational product for bipolar depression. It is a global study taking place at multiple centers. The study is \"randomized\" and \"double-blind,\" which means you will be assigned by chance (like a coin flip) to receive either the investigational product or a placebo, a pill with no active medicine. Neither you nor your study doctor will know which treatment you are receiving, which helps ensure the results are unbiased. Your total participation in the study will last for approximately 18 weeks, which includes screening, a 6-week treatment period, and an 8-week follow-up period.\n\nThis study is looking for adults between the ages of 18 and 74 who have been diagnosed with Bipolar I or Bipolar II disorder and are currently experiencing a moderate to severe depressive episode. To be eligible, your current depressive episode must have lasted between 4 weeks and 12 months, and you must meet specific scores on depression rating scales. You may not be able to participate if you have recently had suicidal plans, have been found to be resistant to two or more previous treatments for your current episode, or are taking certain other psychiatric medications. The study team will review all eligibility criteria with you to determine if this study is a good fit.\n\nIf you join the study, you will take one capsule by mouth each day for 6 weeks; this will be either the investigational product or a placebo. The main purpose of the study is to see if the investigational product can reduce symptoms of depression more effectively than a placebo, which will be measured using a standard depression questionnaire (the MADRS). Researchers will also assess the product's effects on the loss of pleasure (anhedonia), its safety, and how quickly it may begin to work. Your participation will involve regular visits to the study center for assessments, which include questionnaires, vital signs checks, blood tests, and heart tracings (ECGs).",
                  "total_sites": 1,
                  "similarity_score": 0.7513187012769589
                },
                {
                  "id": 102,
                  "trial_name": "A Phase 4, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 Variant-Containing Formulation in Adults 50 to 64 Years of Age Without Underlying Conditions that puts them at High Risk for Severe Outcomes from COVID-19",
                  "conditions": "COVID-19",
                  "description": "This is a Phase 4 clinical research study sponsored by ModernaTX, Inc., which means it is being conducted after the vaccines have already been approved to gather additional information. The study is randomized, meaning participants will be assigned by chance, like flipping a coin, to one of three groups. It is also observer-blind, so you and the main study team will not know if you received a vaccine or a placebo (an injection with no active ingredient), though the staff preparing the injection will know. This multicenter study will be conducted at various research sites and will follow each participant for approximately 6 months to collect important post-marketing data on vaccine performance in the current environment.\n\nTo be eligible for this study, you must be between 50 and 64 years of age and not have any underlying medical conditions that the CDC considers high-risk for severe COVID-19, such as cancer, chronic lung or kidney disease, diabetes, or certain heart conditions. You cannot participate if you have received any COVID-19 vaccine within the 3 months before enrolling or if you have previously had a laboratory-confirmed case of COVID-19. The study aims to enroll up to 30,000 participants who meet these criteria. If you are a female of childbearing potential, you must agree to use effective contraception during the initial phase of the study.\n\nIf you join the study, you will receive a single injection of either the mRNA-1283 vaccine, the mRNA-1273 (SPIKEVAX\u00ae) vaccine, or a placebo. The primary goals are to measure how effective the vaccines are at preventing symptomatic COVID-19 and to carefully monitor their safety. Your participation will involve a clinic visit on Day 1 for screening and the injection, a safety phone call on Day 8, another clinic visit on Day 29, and a final safety call at the end of the study around 6 months. You will be asked to use an electronic diary to report any symptoms, and if you feel sick with COVID-19 symptoms, you will need to visit the clinic for a nasal swab test. Blood samples may also be collected to measure your body's immune response.",
                  "investigator_name": "Dr. Melissa\tJones",
                  "site_location": "Charlotte, NC",
                  "protocol_summary": "This is a Phase 4 clinical research study sponsored by ModernaTX, Inc., which means it is being conducted after the vaccines have already been approved to gather additional information. The study is randomized, meaning participants will be assigned by chance, like flipping a coin, to one of three groups. It is also observer-blind, so you and the main study team will not know if you received a vaccine or a placebo (an injection with no active ingredient), though the staff preparing the injection will know. This multicenter study will be conducted at various research sites and will follow each participant for approximately 6 months to collect important post-marketing data on vaccine performance in the current environment.\n\nTo be eligible for this study, you must be between 50 and 64 years of age and not have any underlying medical conditions that the CDC considers high-risk for severe COVID-19, such as cancer, chronic lung or kidney disease, diabetes, or certain heart conditions. You cannot participate if you have received any COVID-19 vaccine within the 3 months before enrolling or if you have previously had a laboratory-confirmed case of COVID-19. The study aims to enroll up to 30,000 participants who meet these criteria. If you are a female of childbearing potential, you must agree to use effective contraception during the initial phase of the study.\n\nIf you join the study, you will receive a single injection of either the mRNA-1283 vaccine, the mRNA-1273 (SPIKEVAX\u00ae) vaccine, or a placebo. The primary goals are to measure how effective the vaccines are at preventing symptomatic COVID-19 and to carefully monitor their safety. Your participation will involve a clinic visit on Day 1 for screening and the injection, a safety phone call on Day 8, another clinic visit on Day 29, and a final safety call at the end of the study around 6 months. You will be asked to use an electronic diary to report any symptoms, and if you feel sick with COVID-19 symptoms, you will need to visit the clinic for a nasal swab test. Blood samples may also be collected to measure your body's immune response.",
                  "total_sites": 18,
                  "similarity_score": 0.738847441346397
                },
                {
                  "id": 106,
                  "trial_name": "A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study of Modified Release RTN-001 In Patients with Uncontrolled Hypertension",
                  "conditions": "Uncontrolled Hypertension",
                  "description": "This is a Phase 2b clinical research study sponsored by Retension Pharmaceuticals, Inc., which will take place at multiple medical centers across the United States. The study is designed as a randomized, double-blind, placebo-controlled trial, which means you will be assigned by chance (like a coin toss) to receive either the investigational drug or a placebo (an inactive substance). Neither you nor your study doctor will know which treatment you are receiving, which helps ensure the results are unbiased. Your total participation will last approximately 16 weeks, which includes an initial screening and run-in period, a 12-week treatment period, and a final follow-up phone call two weeks after your last dose.\n\nThis study is seeking approximately 280 adults between the ages of 18 and 70 who have uncontrolled high blood pressure. To be eligible, you must currently be taking a stable regimen of two or more blood pressure medications, but still have a blood pressure reading of at least 130/80 mm Hg. There are several reasons you may not be able to participate, such as having very high blood pressure (over 170/110 mm Hg), a recent history of a heart attack or stroke, or current use of certain medications like nitrates or alpha-blockers. The study aims to enroll a diverse population, including patients with resistant hypertension who are on three or more medications.\n\nIf you qualify and choose to participate, you will first complete a 2-week period taking a placebo to ensure you can follow the study requirements. Afterwards, you will be randomly assigned to take a once-daily pill for 12 weeks, which will be one of three different doses of the investigational drug RTN-001 or a matching placebo. The main purpose of the study is to see if RTN-001 can effectively lower systolic blood pressure. Throughout the study, you will attend several clinic visits (at weeks 2, 4, 8, and 12) for procedures that include blood pressure measurements in the office, wearing a 24-hour blood pressure monitor at home, blood tests, heart tracings (ECGs), and physical exams.",
                  "investigator_name": "Dr. Melissa\tJones",
                  "site_location": "Charlotte, NC",
                  "protocol_summary": "This is a Phase 2b clinical research study sponsored by Retension Pharmaceuticals, Inc., which will take place at multiple medical centers across the United States. The study is designed as a randomized, double-blind, placebo-controlled trial, which means you will be assigned by chance (like a coin toss) to receive either the investigational drug or a placebo (an inactive substance). Neither you nor your study doctor will know which treatment you are receiving, which helps ensure the results are unbiased. Your total participation will last approximately 16 weeks, which includes an initial screening and run-in period, a 12-week treatment period, and a final follow-up phone call two weeks after your last dose.\n\nThis study is seeking approximately 280 adults between the ages of 18 and 70 who have uncontrolled high blood pressure. To be eligible, you must currently be taking a stable regimen of two or more blood pressure medications, but still have a blood pressure reading of at least 130/80 mm Hg. There are several reasons you may not be able to participate, such as having very high blood pressure (over 170/110 mm Hg), a recent history of a heart attack or stroke, or current use of certain medications like nitrates or alpha-blockers. The study aims to enroll a diverse population, including patients with resistant hypertension who are on three or more medications.\n\nIf you qualify and choose to participate, you will first complete a 2-week period taking a placebo to ensure you can follow the study requirements. Afterwards, you will be randomly assigned to take a once-daily pill for 12 weeks, which will be one of three different doses of the investigational drug RTN-001 or a matching placebo. The main purpose of the study is to see if RTN-001 can effectively lower systolic blood pressure. Throughout the study, you will attend several clinic visits (at weeks 2, 4, 8, and 12) for procedures that include blood pressure measurements in the office, wearing a 24-hour blood pressure monitor at home, blood tests, heart tracings (ECGs), and physical exams.",
                  "total_sites": 8,
                  "similarity_score": 0.7233745688953409
                }
              ],
              "semantic_search": true
            },
            "response_time": 17.257435083389282,
            "timestamp": "2025-12-15T21:54:03.696593"
          },
          {
            "user_message": "Yes, check my eligibility",
            "bot_response": "Great! I'll help you check your eligibility.\n\nI need to ask you a few questions about the alzheimers trial.\n\n**Question 1 of 4:** How old were you when this condition first started?",
            "metadata": {
              "session_id": "AUTO_TEST_random_000",
              "current_state": "prescreening_active",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "start_prescreening",
              "entities_collected": {
                "condition": null,
                "location": null,
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": "yes",
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "start_prescreening",
                "parameters": {},
                "response_text": "Of course, I can help with that. I'll ask a few simple questions to see if you might be a match for any of these trials. To start, could you please tell me your age?",
                "new_state": "prescreening_started",
                "collect_entities": [
                  "age"
                ],
                "metadata": {
                  "reasoning": "The user has explicitly confirmed their desire to check eligibility ('Yes, check my eligibility') after being shown a list of trials (state: 'trials_shown'). The most appropriate action is to initiate the prescreening process. The response confirms this, sets expectations, and asks the first common eligibility question (age) to begin the questionnaire. The state is updated to 'prescreening_started' to reflect this new phase of the conversation."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "prescreening_started": true,
              "trial_id": 112,
              "trial_name": "A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Investigational Product in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)",
              "current_question_index": 0,
              "total_questions": 4,
              "current_question": "How old were you when this condition first started?",
              "expected_answer_type": "number"
            },
            "response_time": 17.225563764572144,
            "timestamp": "2025-12-15T21:54:20.923189"
          },
          {
            "user_message": "62",
            "bot_response": "I had trouble processing your answer. There seems to be an issue with the prescreening system. Please try searching for trials again.",
            "metadata": {
              "session_id": "AUTO_TEST_random_000",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "continue_prescreening",
              "entities_collected": {
                "condition": null,
                "location": null,
                "age": 62,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "continue_prescreening",
                "parameters": {},
                "response_text": "Got it, thanks for sharing that. The next question is: Have you had an amyloid PET scan or a lumbar puncture that confirmed the presence of amyloid plaques?",
                "new_state": "prescreening_active",
                "collect_entities": [
                  "boolean_answer"
                ],
                "metadata": {
                  "reasoning": "The user is in an active prescreening session (`prescreening_active` state) and has just provided their age in response to a previous question. The correct action is to continue the prescreening process by acknowledging their answer and asking the next question in the sequence to determine their eligibility. The state remains `prescreening_active` as the process is ongoing."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "prescreening_error": "failed_to_process_answer",
              "error_details": "'coroutine' object has no attribute 'criterion_id'",
              "error_type": "AttributeError"
            },
            "response_time": 19.172525882720947,
            "timestamp": "2025-12-15T21:54:40.096383"
          }
        ],
        "final_state": "completed",
        "total_turns": 3,
        "total_questions_asked": 4,
        "errors": [
          {
            "type": "unexpected_state",
            "bot_response": "I had trouble processing your answer. There seems to be an issue with the prescreening system. Please try searching for trials again."
          }
        ]
      },
      "validation": {
        "passed": false,
        "overall_score": 70.0,
        "crash_prevention": {
          "passed": true,
          "score": 100.0,
          "error_count": 0,
          "errors": [],
          "failures": []
        },
        "eligibility_accuracy": {
          "passed": false,
          "score": 0.0,
          "reason": "Could not extract eligibility result",
          "failures": [
            {
              "type": "eligibility_logic_error",
              "reason": "No eligibility determination found in conversation",
              "likely_location": "core/prescreening/gemini_prescreening_manager.py:evaluate_eligibility()",
              "severity": "high"
            }
          ]
        },
        "conversation_quality": {
          "passed": true,
          "score": 100.0,
          "total_questions_asked": 4,
          "issues": [],
          "failures": []
        },
        "edge_case_handling": {
          "passed": true,
          "score": 100.0,
          "applicable": false,
          "failures": []
        },
        "performance": {
          "passed": true,
          "score": 70.0,
          "avg_response_time": 17.88517491022746,
          "max_response_time": 19.172525882720947,
          "status": "acceptable",
          "failures": []
        },
        "failure_points": [
          {
            "type": "eligibility_logic_error",
            "reason": "No eligibility determination found in conversation",
            "likely_location": "core/prescreening/gemini_prescreening_manager.py:evaluate_eligibility()",
            "severity": "high"
          }
        ],
        "recommendations": [
          "\u26a0\ufe0f HIGH: Review eligibility evaluation logic in gemini_prescreening_manager.py"
        ]
      },
      "timestamp": "2025-12-15T21:54:40.096604"
    },
    {
      "patient_id": "AUTO_TEST_targeted_psoriasis_000",
      "patient_profile": {
        "patient_id": "AUTO_TEST_targeted_psoriasis_000",
        "profile_type": "targeted",
        "demographics": {
          "age": 31,
          "gender": "male",
          "location": "Jackson, MS",
          "name": "Test Psoriasis Patient",
          "first_name": "Test",
          "last_name": "Patient"
        },
        "medical_history": {
          "primary_condition": "Psoriasis",
          "conditions": [
            "Plaque Psoriasis"
          ],
          "medications": [
            "Topical Corticosteroids"
          ],
          "duration_years": 5,
          "pasi_score": 15,
          "body_surface_area": "20%"
        },
        "expected_behavior": {
          "should_find_trials": true,
          "likely_eligible": true,
          "expected_question_count_range": [
            4,
            7
          ],
          "target_trial_keywords": [
            "psoriasis",
            "dermatology"
          ]
        }
      },
      "conversation_result": {
        "session_id": "AUTO_TEST_targeted_psoriasis_000",
        "patient_id": "AUTO_TEST_targeted_psoriasis_000",
        "conversation_log": [
          {
            "user_message": "Psoriasis trials in Jackson, MS",
            "bot_response": "I couldn't find any trials for Psoriasis in Jackson, MS at the moment. Would you like to try a different condition or location?",
            "metadata": {
              "session_id": "AUTO_TEST_targeted_psoriasis_000",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "search_trials",
              "entities_collected": {
                "condition": "Psoriasis",
                "location": "Jackson",
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "search_trials",
                "parameters": {
                  "condition": "Psoriasis",
                  "location": "Jackson, MS"
                },
                "response_text": "Of course. I can certainly look for psoriasis clinical trials in Jackson, MS for you. One moment while I search.",
                "new_state": "awaiting_search_results",
                "collect_entities": [],
                "metadata": {
                  "reasoning": "The user has provided both a specific condition ('Psoriasis') and a location ('Jackson, MS'), which are the two required pieces of information to perform a trial search. The `search_trials` action is the most direct and helpful next step to fulfill the user's explicit request."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "no_trials_found": true,
              "condition": "Psoriasis",
              "location": "Jackson, MS"
            },
            "response_time": 15.975252866744995,
            "timestamp": "2025-12-15T21:54:02.389130"
          },
          {
            "user_message": "Yes, check my eligibility",
            "bot_response": "I need to know which specific trial you'd like to check eligibility for. Could you please search for trials first, or let me know what condition and location you're interested in?",
            "metadata": {
              "session_id": "AUTO_TEST_targeted_psoriasis_000",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "start_prescreening",
              "entities_collected": {
                "condition": null,
                "location": null,
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": true,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "start_prescreening",
                "parameters": {},
                "response_text": "Great, I can help with that. To check your eligibility for psoriasis trials near Jackson, I'll need to ask a few questions. First, could you please tell me your age?",
                "new_state": "prescreening",
                "collect_entities": [
                  "age"
                ],
                "metadata": {
                  "reasoning": "The user has explicitly confirmed they want to check their eligibility. We have the necessary condition (Psoriasis) and location (Jackson) to proceed. The most appropriate action is to start the prescreening process by asking the first common eligibility question, which is typically age. This moves the conversation forward toward the user's goal. The state is updated to 'prescreening' to reflect this new phase."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "prescreening_error": "no_trial_id_found"
            },
            "response_time": 19.76747965812683,
            "timestamp": "2025-12-15T21:54:22.158020"
          },
          {
            "user_message": "Jackson, MS",
            "bot_response": "I couldn't find any trials for Psoriasis in Jackson, MS at the moment. Would you like to try a different condition or location?",
            "metadata": {
              "session_id": "AUTO_TEST_targeted_psoriasis_000",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "search_trials",
              "entities_collected": {
                "condition": null,
                "location": "Jackson, MS",
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "search_trials",
                "parameters": {
                  "condition": "Psoriasis",
                  "location": "Jackson, MS"
                },
                "response_text": "Perfect, thank you for confirming Jackson, MS. I have what I need to look for Psoriasis trials in your area.\n\nI'll pull up a list for you in just a moment. If any of them seem like a good match, we can walk through some questions to check the basic eligibility requirements. Sound good?",
                "new_state": "trials_presented",
                "collect_entities": [],
                "metadata": {
                  "reasoning": "The user has provided their location, and their condition (Psoriasis) is already known from the conversation context. With both the necessary pieces of information collected, the most appropriate action is to fulfill the user's intent by searching for clinical trials."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "no_trials_found": true,
              "condition": "Psoriasis",
              "location": "Jackson, MS"
            },
            "response_time": 20.82845425605774,
            "timestamp": "2025-12-15T21:54:42.988590"
          },
          {
            "user_message": "Jackson, MS",
            "bot_response": "I couldn't find any trials for Psoriasis in Jackson, MS at the moment. Would you like to try a different condition or location?",
            "metadata": {
              "session_id": "AUTO_TEST_targeted_psoriasis_000",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "search_trials",
              "entities_collected": {
                "condition": null,
                "location": "Jackson, MS",
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "search_trials",
                "parameters": {
                  "condition": "Psoriasis",
                  "location": "Jackson, MS"
                },
                "response_text": "Thanks for confirming. I've run the search again for Psoriasis trials in Jackson, MS, but unfortunately, it seems there are no matching studies directly in the city right now. This can change, as new trials start all the time. \n\nWould you like me to broaden the search to see if there are any trials in the surrounding areas or statewide in Mississippi?",
                "new_state": "awaiting_search_radius_confirmation",
                "collect_entities": [
                  "boolean_answer"
                ],
                "metadata": {
                  "reasoning": "The user is re-stating their location, indicating a clear intent to search for trials. The best action is to perform the search again as requested. However, based on the conversation history, this search is likely to yield no results. To be helpful and proactive, the response acknowledges the repeated search, delivers the likely negative result empathetically, and immediately offers a constructive next step: broadening the search radius. This anticipates the user's ultimate goal of finding a trial and prevents the conversation from stalling."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "no_trials_found": true,
              "condition": "Psoriasis",
              "location": "Jackson, MS"
            },
            "response_time": 26.84646701812744,
            "timestamp": "2025-12-15T21:55:09.835980"
          },
          {
            "user_message": "Jackson, MS",
            "bot_response": "I couldn't find any trials for Psoriasis in Jackson, MS at the moment. Would you like to try a different condition or location?",
            "metadata": {
              "session_id": "AUTO_TEST_targeted_psoriasis_000",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "search_trials",
              "entities_collected": {
                "condition": null,
                "location": "Jackson, MS",
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "search_trials",
                "parameters": {
                  "condition": "Psoriasis",
                  "location": "Jackson, MS"
                },
                "response_text": "Got it, Jackson, MS. I'll start looking for Psoriasis clinical trials in that area for you right away. This should just take a moment.",
                "new_state": "trials_found",
                "collect_entities": [],
                "metadata": {
                  "reasoning": "The user has provided their location, and we already have their condition (Psoriasis) from the conversation context. With both necessary pieces of information, the next logical and most helpful action is to execute the search for clinical trials. The response confirms the action and sets expectations for the user, moving the conversation forward."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "no_trials_found": true,
              "condition": "Psoriasis",
              "location": "Jackson, MS"
            },
            "response_time": 21.346596240997314,
            "timestamp": "2025-12-15T21:55:31.183141"
          },
          {
            "user_message": "Jackson, MS",
            "bot_response": "I couldn't find any trials for Psoriasis in Jackson, MS at the moment. Would you like to try a different condition or location?",
            "metadata": {
              "session_id": "AUTO_TEST_targeted_psoriasis_000",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "search_trials",
              "entities_collected": {
                "condition": null,
                "location": "Jackson, MS",
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "search_trials",
                "parameters": {
                  "condition": "Psoriasis",
                  "location": "Jackson, MS"
                },
                "response_text": "Great, thank you. I'll search for Psoriasis clinical trials near Jackson, MS. One moment while I look for studies in your area.",
                "new_state": "search_initiated",
                "collect_entities": [],
                "metadata": {
                  "reasoning": "The user has provided a location, and the system already has their condition (Psoriasis) from the conversation context. With both required pieces of information, the most appropriate and helpful action is to proceed with the clinical trial search as implicitly requested by the user's message."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "no_trials_found": true,
              "condition": "Psoriasis",
              "location": "Jackson, MS"
            },
            "response_time": 20.405314922332764,
            "timestamp": "2025-12-15T21:55:51.588754"
          },
          {
            "user_message": "Jackson, MS",
            "bot_response": "I couldn't find any trials for Psoriasis in Jackson, MS at the moment. Would you like to try a different condition or location?",
            "metadata": {
              "session_id": "AUTO_TEST_targeted_psoriasis_000",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "search_trials",
              "entities_collected": {
                "condition": null,
                "location": "Jackson, MS",
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "search_trials",
                "parameters": {
                  "condition": "Psoriasis",
                  "location": "Jackson, MS"
                },
                "response_text": "I've double-checked for Psoriasis trials specifically in Jackson, MS, but unfortunately, it seems there are no active studies listed there right now. Clinical trials can change frequently, though. Would you be open to me expanding the search to a wider area, like nearby cities or the entire state of Mississippi?",
                "new_state": "awaiting_wider_search_confirmation",
                "collect_entities": [
                  "boolean_answer"
                ],
                "metadata": {
                  "reasoning": "The user is re-stating their location, indicating they want to search there despite the previous negative result. The system has both the condition and location. The correct action is to perform the search again to confirm. However, since the previous search was unsuccessful, the response should anticipate the same outcome, gently inform the user, and proactively offer a helpful next step (expanding the search radius). This avoids a conversational dead-end and demonstrates a commitment to helping the user find options."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "no_trials_found": true,
              "condition": "Psoriasis",
              "location": "Jackson, MS"
            },
            "response_time": 16.44307518005371,
            "timestamp": "2025-12-15T21:56:08.032988"
          },
          {
            "user_message": "Jackson, MS",
            "bot_response": "Thanks for confirming your location in Jackson, MS. I wasn't able to find any matching psoriasis trials right in your immediate area with my last search. Would you be open to expanding the search to a wider area, like the entire state of Mississippi?",
            "metadata": {
              "session_id": "AUTO_TEST_targeted_psoriasis_000",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "clarify_request",
              "entities_collected": {
                "condition": null,
                "location": "Jackson, MS",
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "clarify_request",
                "parameters": {},
                "response_text": "Thanks for confirming your location in Jackson, MS. I wasn't able to find any matching psoriasis trials right in your immediate area with my last search. Would you be open to expanding the search to a wider area, like the entire state of Mississippi?",
                "new_state": "awaiting_clarification",
                "collect_entities": [],
                "metadata": {
                  "reasoning": "The user is repeating their location after a search has already been performed for that location and yielded no results. Running the same search again would be unhelpful and create a frustrating loop. The best course of action is to acknowledge their input, clarify that no trials were found in the immediate area, and proactively suggest a solution, such as expanding the search radius. This moves the conversation forward constructively."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "general_response": true
            },
            "response_time": 18.84143090248108,
            "timestamp": "2025-12-15T21:56:26.875398"
          },
          {
            "user_message": "Jackson, MS",
            "bot_response": "Thanks for confirming you're looking for trials in Jackson, MS. I've double-checked, and unfortunately, there don't seem to be any Psoriasis trials recruiting right in that specific area at the moment.\n\nWould you be open to me expanding the search to the entire state of Mississippi? We could also look into remote trials that you might be able to participate in from home.",
            "metadata": {
              "session_id": "AUTO_TEST_targeted_psoriasis_000",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "clarify_request",
              "entities_collected": {
                "condition": null,
                "location": "Jackson, MS",
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "clarify_request",
                "parameters": {},
                "response_text": "Thanks for confirming you're looking for trials in Jackson, MS. I've double-checked, and unfortunately, there don't seem to be any Psoriasis trials recruiting right in that specific area at the moment.\n\nWould you be open to me expanding the search to the entire state of Mississippi? We could also look into remote trials that you might be able to participate in from home.",
                "new_state": "awaiting_clarification",
                "collect_entities": [],
                "metadata": {
                  "reasoning": "The user is repeating their location after a previous search likely yielded no results, indicating they are stuck in a conversational loop. Simply searching again for 'Jackson, MS' would be unhelpful and frustrating. The best course of action is to acknowledge their request, confirm the lack of local trials, and proactively offer alternative, constructive solutions. By suggesting a wider search (statewide) or a different type of trial (remote), we break the loop, show empathy for their situation, and provide clear, helpful next steps to move the conversation forward."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "general_response": true
            },
            "response_time": 25.76311492919922,
            "timestamp": "2025-12-15T21:56:52.639062"
          },
          {
            "user_message": "Yes, that's correct",
            "bot_response": "I'm happy to help with that! To make sure I get you the right information, could you clarify which option you'd prefer? Should I expand the search to include all of Mississippi, or would you like to look for trials that can be done remotely from home?",
            "metadata": {
              "session_id": "AUTO_TEST_targeted_psoriasis_000",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "clarify_request",
              "entities_collected": {
                "condition": null,
                "location": null,
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": true,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "clarify_request",
                "parameters": {},
                "response_text": "I'm happy to help with that! To make sure I get you the right information, could you clarify which option you'd prefer? Should I expand the search to include all of Mississippi, or would you like to look for trials that can be done remotely from home?",
                "new_state": "awaiting_clarification",
                "collect_entities": [],
                "metadata": {
                  "reasoning": "The user's response 'Yes' is ambiguous because the previous turn offered two distinct options: expanding the search to the entire state or looking for remote trials. The chosen action is to ask for clarification to determine which path the user wants to take before proceeding with a new search. This ensures the next step is accurate and helpful."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "general_response": true
            },
            "response_time": 18.116605281829834,
            "timestamp": "2025-12-15T21:57:10.756236"
          },
          {
            "user_message": "I'm not sure, can you clarify?",
            "bot_response": "Of course, I'm happy to clarify. \n\n1. **Expanding the search area:** This means we would look for trials in a larger radius around Jackson, MS. This could give you more options, but might require you to travel for study visits.\n\n2. **Searching for remote trials:** This means we would look for studies you can participate in from home. These are often called 'virtual' trials and might involve telehealth appointments or using a mobile app.\n\nWhich of these approaches sounds better to you?",
            "metadata": {
              "session_id": "AUTO_TEST_targeted_psoriasis_000",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "general_response",
              "entities_collected": {
                "condition": null,
                "location": null,
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "general_response",
                "parameters": {},
                "response_text": "Of course, I'm happy to clarify. \n\n1. **Expanding the search area:** This means we would look for trials in a larger radius around Jackson, MS. This could give you more options, but might require you to travel for study visits.\n\n2. **Searching for remote trials:** This means we would look for studies you can participate in from home. These are often called 'virtual' trials and might involve telehealth appointments or using a mobile app.\n\nWhich of these approaches sounds better to you?",
                "new_state": "awaiting_search_preference",
                "collect_entities": [],
                "metadata": {
                  "reasoning": "The user has asked for clarification on the two search options presented previously. The best action is to provide a detailed, easy-to-understand explanation of each option ('expand search' vs. 'remote trials') to help them make an informed choice. This is a general conversational response aimed at resolving their uncertainty and guiding them to the next step."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "general_response": true
            },
            "response_time": 20.689116954803467,
            "timestamp": "2025-12-15T21:57:31.445974"
          }
        ],
        "final_state": "failed",
        "total_turns": 11,
        "total_questions_asked": 0,
        "errors": [
          {
            "type": "timeout",
            "message": "I'm not sure, can you clarify?",
            "response_time": 30.96219801902771
          },
          {
            "type": "conversation_failure",
            "error": "",
            "state": "prescreening_active",
            "timestamp": "2025-12-15T21:58:02.408808"
          }
        ]
      },
      "validation": {
        "passed": false,
        "overall_score": 11.0,
        "crash_prevention": {
          "passed": false,
          "score": 0.0,
          "error_count": 2,
          "errors": [
            {
              "type": "timeout",
              "message": "I'm not sure, can you clarify?",
              "response_time": 30.96219801902771
            },
            {
              "type": "conversation_failure",
              "error": "",
              "state": "prescreening_active",
              "timestamp": "2025-12-15T21:58:02.408808"
            }
          ],
          "failures": [
            {
              "type": "crash",
              "error_type": "timeout",
              "error_message": "Unknown error",
              "likely_location": "aiohttp timeout in conversation_simulator.py or slow Gemini API response",
              "severity": "critical"
            },
            {
              "type": "crash",
              "error_type": "conversation_failure",
              "error_message": "",
              "likely_location": "Unknown - check full error trace",
              "severity": "critical"
            }
          ]
        },
        "eligibility_accuracy": {
          "passed": false,
          "score": 0.0,
          "reason": "Prescreening did not complete",
          "failures": [
            {
              "type": "eligibility_logic_error",
              "reason": "Prescreening flow did not complete",
              "final_state": "failed",
              "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py",
              "severity": "high"
            }
          ]
        },
        "conversation_quality": {
          "passed": false,
          "score": 5.0,
          "total_questions_asked": 0,
          "issues": [
            "Too few questions asked (0, expected at least 4)",
            "Repeated question: I couldn't find any trials for Psoriasis in Jackso...",
            "Repeated question: I couldn't find any trials for Psoriasis in Jackso...",
            "Repeated question: I couldn't find any trials for Psoriasis in Jackso...",
            "Repeated question: I couldn't find any trials for Psoriasis in Jackso...",
            "Repeated question: I couldn't find any trials for Psoriasis in Jackso..."
          ],
          "failures": [
            {
              "type": "conversation_quality_issue",
              "issue": "Too few questions asked (0, expected at least 4)",
              "severity": "medium",
              "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
            },
            {
              "type": "conversation_quality_issue",
              "issue": "Repeated question: I couldn't find any trials for Psoriasis in Jackso...",
              "severity": "medium",
              "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
            },
            {
              "type": "conversation_quality_issue",
              "issue": "Repeated question: I couldn't find any trials for Psoriasis in Jackso...",
              "severity": "medium",
              "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
            },
            {
              "type": "conversation_quality_issue",
              "issue": "Repeated question: I couldn't find any trials for Psoriasis in Jackso...",
              "severity": "medium",
              "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
            },
            {
              "type": "conversation_quality_issue",
              "issue": "Repeated question: I couldn't find any trials for Psoriasis in Jackso...",
              "severity": "medium",
              "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
            },
            {
              "type": "conversation_quality_issue",
              "issue": "Repeated question: I couldn't find any trials for Psoriasis in Jackso...",
              "severity": "medium",
              "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
            }
          ]
        },
        "edge_case_handling": {
          "passed": true,
          "score": 100.0,
          "applicable": false,
          "failures": []
        },
        "performance": {
          "passed": false,
          "score": 40.0,
          "avg_response_time": 20.456628019159492,
          "max_response_time": 26.84646701812744,
          "status": "slow",
          "failures": [
            {
              "type": "performance_issue",
              "avg_response_time": 20.456628019159492,
              "max_response_time": 26.84646701812744,
              "severity": "low",
              "recommendation": "Investigate slow API responses or Gemini API delays"
            }
          ]
        },
        "failure_points": [
          {
            "type": "crash",
            "error_type": "timeout",
            "error_message": "Unknown error",
            "likely_location": "aiohttp timeout in conversation_simulator.py or slow Gemini API response",
            "severity": "critical"
          },
          {
            "type": "crash",
            "error_type": "conversation_failure",
            "error_message": "",
            "likely_location": "Unknown - check full error trace",
            "severity": "critical"
          },
          {
            "type": "eligibility_logic_error",
            "reason": "Prescreening flow did not complete",
            "final_state": "failed",
            "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py",
            "severity": "high"
          },
          {
            "type": "conversation_quality_issue",
            "issue": "Too few questions asked (0, expected at least 4)",
            "severity": "medium",
            "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
          },
          {
            "type": "conversation_quality_issue",
            "issue": "Repeated question: I couldn't find any trials for Psoriasis in Jackso...",
            "severity": "medium",
            "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
          },
          {
            "type": "conversation_quality_issue",
            "issue": "Repeated question: I couldn't find any trials for Psoriasis in Jackso...",
            "severity": "medium",
            "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
          },
          {
            "type": "conversation_quality_issue",
            "issue": "Repeated question: I couldn't find any trials for Psoriasis in Jackso...",
            "severity": "medium",
            "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
          },
          {
            "type": "conversation_quality_issue",
            "issue": "Repeated question: I couldn't find any trials for Psoriasis in Jackso...",
            "severity": "medium",
            "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
          },
          {
            "type": "conversation_quality_issue",
            "issue": "Repeated question: I couldn't find any trials for Psoriasis in Jackso...",
            "severity": "medium",
            "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
          },
          {
            "type": "performance_issue",
            "avg_response_time": 20.456628019159492,
            "max_response_time": 26.84646701812744,
            "severity": "low",
            "recommendation": "Investigate slow API responses or Gemini API delays"
          }
        ],
        "recommendations": [
          "\ud83d\udea8 CRITICAL: Fix crashes and exceptions. Review error logs and add error handling.",
          "\u26a0\ufe0f HIGH: Review eligibility evaluation logic in gemini_prescreening_manager.py",
          "\u26a0\ufe0f MEDIUM: Major conversation quality issues. Review question generation and response handling.",
          "\u2139\ufe0f LOW: Slow response times. Optimize API calls or consider caching."
        ]
      },
      "timestamp": "2025-12-15T21:58:02.409319"
    },
    {
      "patient_id": "AUTO_TEST_targeted_psoriasis_001",
      "patient_profile": {
        "patient_id": "AUTO_TEST_targeted_psoriasis_001",
        "profile_type": "targeted",
        "demographics": {
          "age": 39,
          "gender": "female",
          "location": "Charlotte, NC",
          "name": "Test Psoriasis Patient",
          "first_name": "Test",
          "last_name": "Patient"
        },
        "medical_history": {
          "primary_condition": "Psoriasis",
          "conditions": [
            "Plaque Psoriasis"
          ],
          "medications": [
            "Topical Corticosteroids"
          ],
          "duration_years": 5,
          "pasi_score": 15,
          "body_surface_area": "20%"
        },
        "expected_behavior": {
          "should_find_trials": true,
          "likely_eligible": true,
          "expected_question_count_range": [
            4,
            7
          ],
          "target_trial_keywords": [
            "psoriasis",
            "dermatology"
          ]
        }
      },
      "conversation_result": {
        "session_id": "AUTO_TEST_targeted_psoriasis_001",
        "patient_id": "AUTO_TEST_targeted_psoriasis_001",
        "conversation_log": [
          {
            "user_message": "Psoriasis trials in Charlotte, NC",
            "bot_response": "Great! I found 5 clinical trial(s) available in Charlotte, NC:\n\n**Dr. Keith Logan**\n  \u2022 Bipolar Depression (1 trial)\n\n**Dr. Melissa\tJones**\n  \u2022 Gout (1 trial)\n  \u2022 Obesity (1 trial)\n  \u2022 Uncontrolled Hypertension (1 trial)\n  \u2022 COVID-19 (1 trial)\n\nWould you like to:\n1. Check your eligibility for any of these trials?\n2. Learn more about a specific condition?\n3. See trials in a different location?",
            "metadata": {
              "session_id": "AUTO_TEST_targeted_psoriasis_001",
              "current_state": "trials_shown",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "search_trials",
              "entities_collected": {
                "condition": "Psoriasis",
                "location": "Charlotte",
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "search_trials",
                "parameters": {
                  "condition": "Psoriasis",
                  "location": "Charlotte, NC"
                },
                "response_text": "Of course. I can certainly look for Psoriasis clinical trials in the Charlotte, NC area for you. Finding the right trial is an important step, and I'm here to help. One moment while I search.\n\nOnce I find some options, we can also go through a few questions to see if you might be a good fit for any of them, if you'd like.",
                "new_state": "awaiting_search_results",
                "collect_entities": [],
                "metadata": {
                  "reasoning": "The user has provided both a specific condition ('Psoriasis') and a location ('Charlotte, NC'), which are the two necessary pieces of information to perform a trial search. The `search_trials` action is the most direct and helpful next step to fulfill the user's explicit request. The response confirms the user's request, expresses empathy, and sets the stage for the next logical step (eligibility prescreening) after the search results are presented."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "trials_found": 5,
              "condition": "Psoriasis",
              "location": "Charlotte, NC",
              "trials_data": [
                {
                  "id": 112,
                  "trial_name": "A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Investigational Product in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)",
                  "conditions": "Bipolar Depression",
                  "description": "This is a Phase 3 clinical research study for a new investigational product for bipolar depression. It is a global study taking place at multiple centers. The study is \"randomized\" and \"double-blind,\" which means you will be assigned by chance (like a coin flip) to receive either the investigational product or a placebo, a pill with no active medicine. Neither you nor your study doctor will know which treatment you are receiving, which helps ensure the results are unbiased. Your total participation in the study will last for approximately 18 weeks, which includes screening, a 6-week treatment period, and an 8-week follow-up period.\n\nThis study is looking for adults between the ages of 18 and 74 who have been diagnosed with Bipolar I or Bipolar II disorder and are currently experiencing a moderate to severe depressive episode. To be eligible, your current depressive episode must have lasted between 4 weeks and 12 months, and you must meet specific scores on depression rating scales. You may not be able to participate if you have recently had suicidal plans, have been found to be resistant to two or more previous treatments for your current episode, or are taking certain other psychiatric medications. The study team will review all eligibility criteria with you to determine if this study is a good fit.\n\nIf you join the study, you will take one capsule by mouth each day for 6 weeks; this will be either the investigational product or a placebo. The main purpose of the study is to see if the investigational product can reduce symptoms of depression more effectively than a placebo, which will be measured using a standard depression questionnaire (the MADRS). Researchers will also assess the product's effects on the loss of pleasure (anhedonia), its safety, and how quickly it may begin to work. Your participation will involve regular visits to the study center for assessments, which include questionnaires, vital signs checks, blood tests, and heart tracings (ECGs).",
                  "investigator_name": "Dr. Keith Logan",
                  "site_location": "Charlotte, NC",
                  "protocol_summary": "This is a Phase 3 clinical research study for a new investigational product for bipolar depression. It is a global study taking place at multiple centers. The study is \"randomized\" and \"double-blind,\" which means you will be assigned by chance (like a coin flip) to receive either the investigational product or a placebo, a pill with no active medicine. Neither you nor your study doctor will know which treatment you are receiving, which helps ensure the results are unbiased. Your total participation in the study will last for approximately 18 weeks, which includes screening, a 6-week treatment period, and an 8-week follow-up period.\n\nThis study is looking for adults between the ages of 18 and 74 who have been diagnosed with Bipolar I or Bipolar II disorder and are currently experiencing a moderate to severe depressive episode. To be eligible, your current depressive episode must have lasted between 4 weeks and 12 months, and you must meet specific scores on depression rating scales. You may not be able to participate if you have recently had suicidal plans, have been found to be resistant to two or more previous treatments for your current episode, or are taking certain other psychiatric medications. The study team will review all eligibility criteria with you to determine if this study is a good fit.\n\nIf you join the study, you will take one capsule by mouth each day for 6 weeks; this will be either the investigational product or a placebo. The main purpose of the study is to see if the investigational product can reduce symptoms of depression more effectively than a placebo, which will be measured using a standard depression questionnaire (the MADRS). Researchers will also assess the product's effects on the loss of pleasure (anhedonia), its safety, and how quickly it may begin to work. Your participation will involve regular visits to the study center for assessments, which include questionnaires, vital signs checks, blood tests, and heart tracings (ECGs).",
                  "total_sites": 1,
                  "similarity_score": 0.7513187012769589
                },
                {
                  "id": 74,
                  "trial_name": "A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Dotinurad Compared With Allopurinol in Adult Participants With Hyperuricemia Associated With Gout",
                  "conditions": "Gout",
                  "description": "This is a Phase 3, randomized, double-blind, multicenter study sponsored by Crystalys Therapeutics, Inc.  The study will be conducted at up to 100 sites across North America and Europe and is expected to last approximately 2.5 years.  \"Double-blind\" means neither you nor your study doctor will know which medicine you are taking. \"Randomized\" means you will be assigned to a treatment group by chance, like flipping a coin.  This helps ensure the results are unbiased.\n\nThis study is for adults with gout who have experienced at least two gout flares in the past year and have been taking a stable dose of allopurinol (300-600mg daily, or 200mg for those with moderate kidney problems) for at least 3 months.  You must also have a serum uric acid (sUA) level of 6.5 mg/dL or higher at two screening visits.  You will not be able to participate if you have certain other medical conditions (these will be discussed during screening).  During the study, you will be asked to keep a diary of your medication intake, any gout flares you experience, and any related healthcare visits.  \n\nIn this study, you will receive either dotinurad (the investigational drug) or allopurinol.  Dotinurad will be given in increasing doses over the first 12 weeks.  Allopurinol will be given at the same dose you were taking before the study began.  The study will measure how well each medication lowers sUA levels in your blood, reduces the number of gout flares you experience, and assess any side effects.  The main goal is to see if dotinurad is as effective as allopurinol in lowering sUA at 24 weeks.  Other goals include evaluating the impact on gout flares and overall safety.  You will have regular check-ups every 2 weeks initially, then every 4 weeks, and will be asked to complete questionnaires about your health.  Even if you stop taking the study medication, you will be encouraged to continue with the follow-up visits.",
                  "investigator_name": "Dr. Melissa\tJones",
                  "site_location": "Charlotte, NC",
                  "protocol_summary": "This is a Phase 3, randomized, double-blind, multicenter study sponsored by Crystalys Therapeutics, Inc.  The study will be conducted at up to 100 sites across North America and Europe and is expected to last approximately 2.5 years.  \"Double-blind\" means neither you nor your study doctor will know which medicine you are taking. \"Randomized\" means you will be assigned to a treatment group by chance, like flipping a coin.  This helps ensure the results are unbiased.\n\nThis study is for adults with gout who have experienced at least two gout flares in the past year and have been taking a stable dose of allopurinol (300-600mg daily, or 200mg for those with moderate kidney problems) for at least 3 months.  You must also have a serum uric acid (sUA) level of 6.5 mg/dL or higher at two screening visits.  You will not be able to participate if you have certain other medical conditions (these will be discussed during screening).  During the study, you will be asked to keep a diary of your medication intake, any gout flares you experience, and any related healthcare visits.  \n\nIn this study, you will receive either dotinurad (the investigational drug) or allopurinol.  Dotinurad will be given in increasing doses over the first 12 weeks.  Allopurinol will be given at the same dose you were taking before the study began.  The study will measure how well each medication lowers sUA levels in your blood, reduces the number of gout flares you experience, and assess any side effects.  The main goal is to see if dotinurad is as effective as allopurinol in lowering sUA at 24 weeks.  Other goals include evaluating the impact on gout flares and overall safety.  You will have regular check-ups every 2 weeks initially, then every 4 weeks, and will be asked to complete questionnaires about your health.  Even if you stop taking the study medication, you will be encouraged to continue with the follow-up visits.",
                  "total_sites": 13,
                  "similarity_score": 0.7284099655273172
                },
                {
                  "id": 85,
                  "trial_name": "A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants without Type 2 Diabetes who are Obese, or Overweight with at Least One Weight-related Comorbid Condition (VANQUISH-1)",
                  "conditions": "Obesity",
                  "description": "This is a Phase 3, randomized, double-blind, placebo-controlled, multi-center study sponsored by Viking Therapeutics Inc.  This means that some participants will receive VK2735 while others receive a placebo, and neither the participants nor the study staff will know who is receiving which.  The study will take place over approximately 88 weeks, including a screening period, 78 weeks of treatment, and a follow-up period. The study aims to evaluate the effectiveness and safety of VK2735 for weight loss.  The locations of the study sites are not specified in this protocol excerpt.\n\nThis study is for adults who are obese (BMI \u226530 kg/m\u00b2) or overweight (BMI \u226527 kg/m\u00b2) with at least one weight-related health issue, but who do *not* have Type 2 Diabetes.  You must be willing to attend regular study visits and follow the study procedures.  Women make up no more than 65% of the participants to ensure enough men are included. The study aims to include people from diverse ethnic and racial backgrounds and those over 65.  If you are eligible and choose to participate, you will be randomly assigned to receive either VK2735 or a placebo.  You will need to attend study visits regularly, especially in the first 33 weeks.\n\nParticipants will receive weekly injections of VK2735 or placebo under the skin. The dose of VK2735 will be gradually increased over several weeks until the target dose is reached.  The study will measure changes in body weight, BMI, waist circumference, blood pressure, cholesterol, and other health indicators.  The main goal is to see if VK2735 is better than placebo at helping people lose weight.  Other goals include assessing the percentage of participants achieving various levels of weight loss (e.g., 5%, 10%, 15%, 20%), and evaluating the impact of VK2735 on blood sugar, cholesterol levels, and quality of life.  Visits will be weekly for the first 33 weeks, then monthly, with self-administered injections between monthly visits.  You will also undergo regular blood tests, vital sign checks, and other assessments.",
                  "investigator_name": "Dr. Melissa\tJones",
                  "site_location": "Charlotte, NC",
                  "protocol_summary": "This is a Phase 3, randomized, double-blind, placebo-controlled, multi-center study sponsored by Viking Therapeutics Inc.  This means that some participants will receive VK2735 while others receive a placebo, and neither the participants nor the study staff will know who is receiving which.  The study will take place over approximately 88 weeks, including a screening period, 78 weeks of treatment, and a follow-up period. The study aims to evaluate the effectiveness and safety of VK2735 for weight loss.  The locations of the study sites are not specified in this protocol excerpt.\n\nThis study is for adults who are obese (BMI \u226530 kg/m\u00b2) or overweight (BMI \u226527 kg/m\u00b2) with at least one weight-related health issue, but who do *not* have Type 2 Diabetes.  You must be willing to attend regular study visits and follow the study procedures.  Women make up no more than 65% of the participants to ensure enough men are included. The study aims to include people from diverse ethnic and racial backgrounds and those over 65.  If you are eligible and choose to participate, you will be randomly assigned to receive either VK2735 or a placebo.  You will need to attend study visits regularly, especially in the first 33 weeks.\n\nParticipants will receive weekly injections of VK2735 or placebo under the skin. The dose of VK2735 will be gradually increased over several weeks until the target dose is reached.  The study will measure changes in body weight, BMI, waist circumference, blood pressure, cholesterol, and other health indicators.  The main goal is to see if VK2735 is better than placebo at helping people lose weight.  Other goals include assessing the percentage of participants achieving various levels of weight loss (e.g., 5%, 10%, 15%, 20%), and evaluating the impact of VK2735 on blood sugar, cholesterol levels, and quality of life.  Visits will be weekly for the first 33 weeks, then monthly, with self-administered injections between monthly visits.  You will also undergo regular blood tests, vital sign checks, and other assessments.",
                  "total_sites": 4,
                  "similarity_score": 0.7231813490114994
                }
              ],
              "semantic_search": true
            },
            "response_time": 18.24676203727722,
            "timestamp": "2025-12-15T21:54:04.661214"
          },
          {
            "user_message": "Yes, check my eligibility",
            "bot_response": "Great! I'll help you check your eligibility.\n\nI need to ask you a few questions about the psoriasis trial.\n\n**Question 1 of 4:** How old were you when this condition first started?",
            "metadata": {
              "session_id": "AUTO_TEST_targeted_psoriasis_001",
              "current_state": "prescreening_active",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "start_prescreening",
              "entities_collected": {
                "condition": null,
                "location": null,
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": "yes",
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "start_prescreening",
                "parameters": {},
                "response_text": "Great! I can help with that. To get started, could you please tell me the name or number of the trial you're most interested in from the list I just showed you? I'll then ask a few questions to see if it might be a good fit.",
                "new_state": "prescreening_started",
                "collect_entities": [
                  "trial_name",
                  "number"
                ],
                "metadata": {
                  "reasoning": "The user has explicitly confirmed they want to check their eligibility after being shown a list of trials. The current state is 'trials_shown'. The most logical next step is to begin the prescreening process. Since the user hasn't specified which trial, the response prompts them to select one from the list they just saw, which is a necessary first step for prescreening."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "prescreening_started": true,
              "trial_id": 112,
              "trial_name": "A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Investigational Product in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)",
              "current_question_index": 0,
              "total_questions": 4,
              "current_question": "How old were you when this condition first started?",
              "expected_answer_type": "number"
            },
            "response_time": 17.33083200454712,
            "timestamp": "2025-12-15T21:54:21.993194"
          },
          {
            "user_message": "39",
            "bot_response": "I had trouble processing your answer. There seems to be an issue with the prescreening system. Please try searching for trials again.",
            "metadata": {
              "session_id": "AUTO_TEST_targeted_psoriasis_001",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "continue_prescreening",
              "entities_collected": {
                "condition": null,
                "location": null,
                "age": 39,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "continue_prescreening",
                "parameters": {},
                "response_text": "Got it. Next question: Have you been diagnosed with moderate to severe plaque psoriasis?",
                "new_state": "prescreening_active",
                "collect_entities": [
                  "boolean_answer"
                ],
                "metadata": {
                  "reasoning": "The user is in an active prescreening state and has just answered a question ('How old were you when this condition first started?'). The correct action is to continue the prescreening process by asking the next question in the sequence to gather more eligibility information. The state remains 'prescreening_active' as the process is ongoing."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "prescreening_error": "failed_to_process_answer",
              "error_details": "'coroutine' object has no attribute 'criterion_id'",
              "error_type": "AttributeError"
            },
            "response_time": 14.409488201141357,
            "timestamp": "2025-12-15T21:54:36.402930"
          }
        ],
        "final_state": "completed",
        "total_turns": 3,
        "total_questions_asked": 4,
        "errors": [
          {
            "type": "unexpected_state",
            "bot_response": "I had trouble processing your answer. There seems to be an issue with the prescreening system. Please try searching for trials again."
          }
        ]
      },
      "validation": {
        "passed": false,
        "overall_score": 70.0,
        "crash_prevention": {
          "passed": true,
          "score": 100.0,
          "error_count": 0,
          "errors": [],
          "failures": []
        },
        "eligibility_accuracy": {
          "passed": false,
          "score": 0.0,
          "reason": "Could not extract eligibility result",
          "failures": [
            {
              "type": "eligibility_logic_error",
              "reason": "No eligibility determination found in conversation",
              "likely_location": "core/prescreening/gemini_prescreening_manager.py:evaluate_eligibility()",
              "severity": "high"
            }
          ]
        },
        "conversation_quality": {
          "passed": true,
          "score": 100.0,
          "total_questions_asked": 4,
          "issues": [],
          "failures": []
        },
        "edge_case_handling": {
          "passed": true,
          "score": 100.0,
          "applicable": false,
          "failures": []
        },
        "performance": {
          "passed": true,
          "score": 70.0,
          "avg_response_time": 16.66236074765523,
          "max_response_time": 18.24676203727722,
          "status": "acceptable",
          "failures": []
        },
        "failure_points": [
          {
            "type": "eligibility_logic_error",
            "reason": "No eligibility determination found in conversation",
            "likely_location": "core/prescreening/gemini_prescreening_manager.py:evaluate_eligibility()",
            "severity": "high"
          }
        ],
        "recommendations": [
          "\u26a0\ufe0f HIGH: Review eligibility evaluation logic in gemini_prescreening_manager.py"
        ]
      },
      "timestamp": "2025-12-15T21:54:36.403174"
    },
    {
      "patient_id": "AUTO_TEST_random_002",
      "patient_profile": {
        "patient_id": "AUTO_TEST_random_002",
        "profile_type": "random",
        "demographics": {
          "age": 70,
          "gender": "male",
          "location": "Charlotte, NC",
          "name": "David Martinez",
          "first_name": "David",
          "last_name": "Martinez"
        },
        "medical_history": {
          "primary_condition": "Alzheimers",
          "conditions": [
            "Alzheimers",
            "Sleep Disorders"
          ],
          "medications": [
            "Donepezil",
            "Memantine"
          ],
          "duration_years": 6
        },
        "expected_behavior": {
          "should_find_trials": true,
          "likely_eligible": true,
          "expected_question_count_range": [
            4,
            8
          ]
        }
      },
      "conversation_result": {
        "session_id": "AUTO_TEST_random_002",
        "patient_id": "AUTO_TEST_random_002",
        "conversation_log": [
          {
            "user_message": "Alzheimers trials in Charlotte, NC",
            "bot_response": "Great! I found 5 clinical trial(s) available in Charlotte, NC:\n\n**Dr. Keith Logan**\n  \u2022 Bipolar Depression (1 trial)\n\n**Dr. Melissa\tJones**\n  \u2022 COVID-19 (2 trials)\n  \u2022 Uncontrolled Hypertension (1 trial)\n  \u2022 Obesity (1 trial)\n\nWould you like to:\n1. Check your eligibility for any of these trials?\n2. Learn more about a specific condition?\n3. See trials in a different location?",
            "metadata": {
              "session_id": "AUTO_TEST_random_002",
              "current_state": "trials_shown",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "search_trials",
              "entities_collected": {
                "condition": "Alzheimers",
                "location": "Charlotte",
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "search_trials",
                "parameters": {
                  "condition": "Alzheimers",
                  "location": "Charlotte, NC"
                },
                "response_text": "Of course. It's completely understandable to explore options for different conditions or locations. I'm now searching for clinical trials for Alzheimer's in Charlotte, NC. I'll share what I find in just a moment.",
                "new_state": "trials_shown",
                "collect_entities": [],
                "metadata": {
                  "reasoning": "The user has provided a new condition ('Alzheimers') and a new location ('Charlotte, NC'), indicating a clear intent to start a new search. The previous context of 'Hypertension' in 'Baton Rouge' is no longer relevant. Since both a condition and location are now available for the new search, the correct action is `search_trials` to find and present the relevant clinical trials."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "trials_found": 5,
              "condition": "Alzheimers",
              "location": "Charlotte, NC",
              "trials_data": [
                {
                  "id": 112,
                  "trial_name": "A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Investigational Product in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)",
                  "conditions": "Bipolar Depression",
                  "description": "This is a Phase 3 clinical research study for a new investigational product for bipolar depression. It is a global study taking place at multiple centers. The study is \"randomized\" and \"double-blind,\" which means you will be assigned by chance (like a coin flip) to receive either the investigational product or a placebo, a pill with no active medicine. Neither you nor your study doctor will know which treatment you are receiving, which helps ensure the results are unbiased. Your total participation in the study will last for approximately 18 weeks, which includes screening, a 6-week treatment period, and an 8-week follow-up period.\n\nThis study is looking for adults between the ages of 18 and 74 who have been diagnosed with Bipolar I or Bipolar II disorder and are currently experiencing a moderate to severe depressive episode. To be eligible, your current depressive episode must have lasted between 4 weeks and 12 months, and you must meet specific scores on depression rating scales. You may not be able to participate if you have recently had suicidal plans, have been found to be resistant to two or more previous treatments for your current episode, or are taking certain other psychiatric medications. The study team will review all eligibility criteria with you to determine if this study is a good fit.\n\nIf you join the study, you will take one capsule by mouth each day for 6 weeks; this will be either the investigational product or a placebo. The main purpose of the study is to see if the investigational product can reduce symptoms of depression more effectively than a placebo, which will be measured using a standard depression questionnaire (the MADRS). Researchers will also assess the product's effects on the loss of pleasure (anhedonia), its safety, and how quickly it may begin to work. Your participation will involve regular visits to the study center for assessments, which include questionnaires, vital signs checks, blood tests, and heart tracings (ECGs).",
                  "investigator_name": "Dr. Keith Logan",
                  "site_location": "Charlotte, NC",
                  "protocol_summary": "This is a Phase 3 clinical research study for a new investigational product for bipolar depression. It is a global study taking place at multiple centers. The study is \"randomized\" and \"double-blind,\" which means you will be assigned by chance (like a coin flip) to receive either the investigational product or a placebo, a pill with no active medicine. Neither you nor your study doctor will know which treatment you are receiving, which helps ensure the results are unbiased. Your total participation in the study will last for approximately 18 weeks, which includes screening, a 6-week treatment period, and an 8-week follow-up period.\n\nThis study is looking for adults between the ages of 18 and 74 who have been diagnosed with Bipolar I or Bipolar II disorder and are currently experiencing a moderate to severe depressive episode. To be eligible, your current depressive episode must have lasted between 4 weeks and 12 months, and you must meet specific scores on depression rating scales. You may not be able to participate if you have recently had suicidal plans, have been found to be resistant to two or more previous treatments for your current episode, or are taking certain other psychiatric medications. The study team will review all eligibility criteria with you to determine if this study is a good fit.\n\nIf you join the study, you will take one capsule by mouth each day for 6 weeks; this will be either the investigational product or a placebo. The main purpose of the study is to see if the investigational product can reduce symptoms of depression more effectively than a placebo, which will be measured using a standard depression questionnaire (the MADRS). Researchers will also assess the product's effects on the loss of pleasure (anhedonia), its safety, and how quickly it may begin to work. Your participation will involve regular visits to the study center for assessments, which include questionnaires, vital signs checks, blood tests, and heart tracings (ECGs).",
                  "total_sites": 1,
                  "similarity_score": 0.7479014873652743
                },
                {
                  "id": 102,
                  "trial_name": "A Phase 4, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 Variant-Containing Formulation in Adults 50 to 64 Years of Age Without Underlying Conditions that puts them at High Risk for Severe Outcomes from COVID-19",
                  "conditions": "COVID-19",
                  "description": "This is a Phase 4 clinical research study sponsored by ModernaTX, Inc., which means it is being conducted after the vaccines have already been approved to gather additional information. The study is randomized, meaning participants will be assigned by chance, like flipping a coin, to one of three groups. It is also observer-blind, so you and the main study team will not know if you received a vaccine or a placebo (an injection with no active ingredient), though the staff preparing the injection will know. This multicenter study will be conducted at various research sites and will follow each participant for approximately 6 months to collect important post-marketing data on vaccine performance in the current environment.\n\nTo be eligible for this study, you must be between 50 and 64 years of age and not have any underlying medical conditions that the CDC considers high-risk for severe COVID-19, such as cancer, chronic lung or kidney disease, diabetes, or certain heart conditions. You cannot participate if you have received any COVID-19 vaccine within the 3 months before enrolling or if you have previously had a laboratory-confirmed case of COVID-19. The study aims to enroll up to 30,000 participants who meet these criteria. If you are a female of childbearing potential, you must agree to use effective contraception during the initial phase of the study.\n\nIf you join the study, you will receive a single injection of either the mRNA-1283 vaccine, the mRNA-1273 (SPIKEVAX\u00ae) vaccine, or a placebo. The primary goals are to measure how effective the vaccines are at preventing symptomatic COVID-19 and to carefully monitor their safety. Your participation will involve a clinic visit on Day 1 for screening and the injection, a safety phone call on Day 8, another clinic visit on Day 29, and a final safety call at the end of the study around 6 months. You will be asked to use an electronic diary to report any symptoms, and if you feel sick with COVID-19 symptoms, you will need to visit the clinic for a nasal swab test. Blood samples may also be collected to measure your body's immune response.",
                  "investigator_name": "Dr. Melissa\tJones",
                  "site_location": "Charlotte, NC",
                  "protocol_summary": "This is a Phase 4 clinical research study sponsored by ModernaTX, Inc., which means it is being conducted after the vaccines have already been approved to gather additional information. The study is randomized, meaning participants will be assigned by chance, like flipping a coin, to one of three groups. It is also observer-blind, so you and the main study team will not know if you received a vaccine or a placebo (an injection with no active ingredient), though the staff preparing the injection will know. This multicenter study will be conducted at various research sites and will follow each participant for approximately 6 months to collect important post-marketing data on vaccine performance in the current environment.\n\nTo be eligible for this study, you must be between 50 and 64 years of age and not have any underlying medical conditions that the CDC considers high-risk for severe COVID-19, such as cancer, chronic lung or kidney disease, diabetes, or certain heart conditions. You cannot participate if you have received any COVID-19 vaccine within the 3 months before enrolling or if you have previously had a laboratory-confirmed case of COVID-19. The study aims to enroll up to 30,000 participants who meet these criteria. If you are a female of childbearing potential, you must agree to use effective contraception during the initial phase of the study.\n\nIf you join the study, you will receive a single injection of either the mRNA-1283 vaccine, the mRNA-1273 (SPIKEVAX\u00ae) vaccine, or a placebo. The primary goals are to measure how effective the vaccines are at preventing symptomatic COVID-19 and to carefully monitor their safety. Your participation will involve a clinic visit on Day 1 for screening and the injection, a safety phone call on Day 8, another clinic visit on Day 29, and a final safety call at the end of the study around 6 months. You will be asked to use an electronic diary to report any symptoms, and if you feel sick with COVID-19 symptoms, you will need to visit the clinic for a nasal swab test. Blood samples may also be collected to measure your body's immune response.",
                  "total_sites": 18,
                  "similarity_score": 0.738847441346397
                },
                {
                  "id": 105,
                  "trial_name": "A Phase 4, Randomized, Double-blind, Placebo-controlled, Post-marketing Study to Evaluate the Efficacy and Safety of an Omicron JN.1 Subvariant SARS-CoV-2 rS Vaccine Adjuvanted with Matrix-M\u00ae in Adults 50 to < 65 Years of Age Without High-risk Conditions for Severe COVID-19",
                  "conditions": "COVID-19",
                  "description": "This is a Phase 4 clinical research study sponsored by Novavax, Inc. to learn more about an investigational COVID-19 vaccine. As a Phase 4 study, it is being conducted after the vaccine has been approved for other groups to gather additional information on its safety and effectiveness. This is a multi-center study, meaning it will take place at up to 90 different locations across the United States. The study is 'randomized' and 'double-blind,' which means you will be assigned by chance to receive either the investigational vaccine or a placebo (an injection with no active ingredient), and neither you nor the study team will know which one you received. Your total participation in the study will last for approximately 6 months.\n\nThis study is seeking approximately 6,500 volunteers who are between 50 and 64 years of age. To be eligible, you must not have any underlying health conditions that put you at high risk for severe COVID-19. If you have received a COVID-19 vaccine before, your last shot must have been at least 90 days before you join this study. The study is open to both men and non-pregnant women who meet these criteria. As a participant, you will help researchers understand how well the vaccine works in a population that is not currently included in the vaccine's approved use.\n\nIf you join the study, you will receive a single injection in your arm on your first visit (Day 0). This injection will be either the investigational Omicron JN.1 vaccine or a placebo. The main purpose of the study is to see if the vaccine can prevent you from getting sick with COVID-19 symptoms. For the next 6 months, the study team will monitor your health and ask you to report any potential COVID-19 symptoms, which would then be confirmed with a PCR test. The study will also track other important health outcomes, such as hospitalizations or any side effects you may experience after the injection.",
                  "investigator_name": "Dr. Melissa\tJones",
                  "site_location": "Charlotte, NC",
                  "protocol_summary": "This is a Phase 4 clinical research study sponsored by Novavax, Inc. to learn more about an investigational COVID-19 vaccine. As a Phase 4 study, it is being conducted after the vaccine has been approved for other groups to gather additional information on its safety and effectiveness. This is a multi-center study, meaning it will take place at up to 90 different locations across the United States. The study is 'randomized' and 'double-blind,' which means you will be assigned by chance to receive either the investigational vaccine or a placebo (an injection with no active ingredient), and neither you nor the study team will know which one you received. Your total participation in the study will last for approximately 6 months.\n\nThis study is seeking approximately 6,500 volunteers who are between 50 and 64 years of age. To be eligible, you must not have any underlying health conditions that put you at high risk for severe COVID-19. If you have received a COVID-19 vaccine before, your last shot must have been at least 90 days before you join this study. The study is open to both men and non-pregnant women who meet these criteria. As a participant, you will help researchers understand how well the vaccine works in a population that is not currently included in the vaccine's approved use.\n\nIf you join the study, you will receive a single injection in your arm on your first visit (Day 0). This injection will be either the investigational Omicron JN.1 vaccine or a placebo. The main purpose of the study is to see if the vaccine can prevent you from getting sick with COVID-19 symptoms. For the next 6 months, the study team will monitor your health and ask you to report any potential COVID-19 symptoms, which would then be confirmed with a PCR test. The study will also track other important health outcomes, such as hospitalizations or any side effects you may experience after the injection.",
                  "total_sites": 7,
                  "similarity_score": 0.7325086811963142
                }
              ],
              "semantic_search": true
            },
            "response_time": 17.602495908737183,
            "timestamp": "2025-12-15T21:58:20.044322"
          },
          {
            "user_message": "Yes, check my eligibility",
            "bot_response": "Great! I'll help you check your eligibility.\n\nI need to ask you a few questions about the alzheimers trial.\n\n**Question 1 of 4:** How old were you when this condition first started?",
            "metadata": {
              "session_id": "AUTO_TEST_random_002",
              "current_state": "prescreening_active",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "start_prescreening",
              "entities_collected": {
                "condition": null,
                "location": null,
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": "yes",
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "start_prescreening",
                "parameters": {},
                "response_text": "Great, I can help with that. To check your eligibility, I'll ask a few simple questions. This will help us see if you might be a match for any of these studies.\n\nFirst, could you please tell me your age?",
                "new_state": "prescreening",
                "collect_entities": [
                  "age"
                ],
                "metadata": {
                  "reasoning": "The user has explicitly confirmed their interest in checking eligibility ('Yes, check my eligibility') after trials were presented (state: 'trials_shown'). The most appropriate action is to begin the prescreening process. The first logical question to ask for most clinical trials, especially for a condition like Alzheimer's, is age. This action transitions the state to 'prescreening' and sets up the collection of the 'age' entity."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "prescreening_started": true,
              "trial_id": 112,
              "trial_name": "A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Investigational Product in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)",
              "current_question_index": 0,
              "total_questions": 4,
              "current_question": "How old were you when this condition first started?",
              "expected_answer_type": "number"
            },
            "response_time": 18.586718797683716,
            "timestamp": "2025-12-15T21:58:38.631665"
          },
          {
            "user_message": "70",
            "bot_response": "I had trouble processing your answer. There seems to be an issue with the prescreening system. Please try searching for trials again.",
            "metadata": {
              "session_id": "AUTO_TEST_random_002",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "continue_prescreening",
              "entities_collected": {
                "condition": null,
                "location": null,
                "age": 70,
                "medication": null,
                "number": 70,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "continue_prescreening",
                "parameters": {
                  "answer": 70
                },
                "response_text": "Thank you for sharing that. For many Alzheimer's studies, it's required to have a study partner\u2014like a family member or caregiver\u2014who can attend appointments with you. Do you have someone who could do that?",
                "new_state": "prescreening_active",
                "collect_entities": [
                  "boolean_answer"
                ],
                "metadata": {
                  "reasoning": "The user is in an active prescreening flow and has provided a direct numerical answer to the previous question. The correct action is to continue the prescreening process by acknowledging their answer and asking the next relevant eligibility question. The question about a study partner is a common and crucial one for Alzheimer's trials. The state remains 'prescreening_active' as the process is not yet complete."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "prescreening_error": "failed_to_process_answer",
              "error_details": "'coroutine' object has no attribute 'criterion_id'",
              "error_type": "AttributeError"
            },
            "response_time": 14.569890975952148,
            "timestamp": "2025-12-15T21:58:53.202368"
          }
        ],
        "final_state": "completed",
        "total_turns": 3,
        "total_questions_asked": 4,
        "errors": [
          {
            "type": "unexpected_state",
            "bot_response": "I had trouble processing your answer. There seems to be an issue with the prescreening system. Please try searching for trials again."
          }
        ]
      },
      "validation": {
        "passed": false,
        "overall_score": 70.0,
        "crash_prevention": {
          "passed": true,
          "score": 100.0,
          "error_count": 0,
          "errors": [],
          "failures": []
        },
        "eligibility_accuracy": {
          "passed": false,
          "score": 0.0,
          "reason": "Could not extract eligibility result",
          "failures": [
            {
              "type": "eligibility_logic_error",
              "reason": "No eligibility determination found in conversation",
              "likely_location": "core/prescreening/gemini_prescreening_manager.py:evaluate_eligibility()",
              "severity": "high"
            }
          ]
        },
        "conversation_quality": {
          "passed": true,
          "score": 100.0,
          "total_questions_asked": 4,
          "issues": [],
          "failures": []
        },
        "edge_case_handling": {
          "passed": true,
          "score": 100.0,
          "applicable": false,
          "failures": []
        },
        "performance": {
          "passed": true,
          "score": 70.0,
          "avg_response_time": 16.919701894124348,
          "max_response_time": 18.586718797683716,
          "status": "acceptable",
          "failures": []
        },
        "failure_points": [
          {
            "type": "eligibility_logic_error",
            "reason": "No eligibility determination found in conversation",
            "likely_location": "core/prescreening/gemini_prescreening_manager.py:evaluate_eligibility()",
            "severity": "high"
          }
        ],
        "recommendations": [
          "\u26a0\ufe0f HIGH: Review eligibility evaluation logic in gemini_prescreening_manager.py"
        ]
      },
      "timestamp": "2025-12-15T21:58:53.203166"
    },
    {
      "patient_id": "AUTO_TEST_random_003",
      "patient_profile": {
        "patient_id": "AUTO_TEST_random_003",
        "profile_type": "random",
        "demographics": {
          "age": 53,
          "gender": "non-binary",
          "location": "New Orleans, LA",
          "name": "Patricia Garcia",
          "first_name": "Patricia",
          "last_name": "Garcia"
        },
        "medical_history": {
          "primary_condition": "Psoriasis",
          "conditions": [
            "Psoriasis",
            "Cardiovascular Disease",
            "Depression"
          ],
          "medications": [
            "Topical Corticosteroids",
            "Methotrexate",
            "Cyclosporine"
          ],
          "duration_years": 10
        },
        "expected_behavior": {
          "should_find_trials": true,
          "likely_eligible": true,
          "expected_question_count_range": [
            4,
            8
          ]
        }
      },
      "conversation_result": {
        "session_id": "AUTO_TEST_random_003",
        "patient_id": "AUTO_TEST_random_003",
        "conversation_log": [
          {
            "user_message": "Psoriasis trials in New Orleans, LA",
            "bot_response": "Great! I found 5 clinical trial(s) available in New Orleans, LA:\n\n**Dr. Patrick Dennis**\n  \u2022 Nonsegmental Vitiligo (1 trial)\n\n**Dr. Deidre Hooper**\n  \u2022 Acne Vulgaris (2 trials)\n  \u2022 Glabellar Lines (1 trial)\n\n**Dr. Lesley Saketkoo**\n  \u2022 Systemic Sclerosis (1 trial)\n\nWould you like to:\n1. Check your eligibility for any of these trials?\n2. Learn more about a specific condition?\n3. See trials in a different location?",
            "metadata": {
              "session_id": "AUTO_TEST_random_003",
              "current_state": "trials_shown",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "search_trials",
              "entities_collected": {
                "condition": "Psoriasis",
                "location": "New Orleans",
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "search_trials",
                "parameters": {
                  "condition": "Psoriasis",
                  "location": "New Orleans, LA"
                },
                "response_text": "Of course, I can help with that. I'm now searching for Psoriasis clinical trials in and around New Orleans, LA. Once I find some options, I can also help you check if you might be eligible by asking a few simple questions. How does that sound?",
                "new_state": "trials_found",
                "collect_entities": [],
                "metadata": {
                  "reasoning": "The user has provided a new condition ('Psoriasis') and a new location ('New Orleans, LA'), which overrides the previous conversation context. Since both pieces of information required for a search are present, the correct action is 'search_trials'. The response acknowledges the new request, confirms the search parameters, and proactively sets the expectation for the next logical step (eligibility prescreening) to guide the conversation forward."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "trials_found": 5,
              "condition": "Psoriasis",
              "location": "New Orleans, LA",
              "trials_data": [
                {
                  "id": 109,
                  "trial_name": "A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Zasocitinib in Participants with Nonsegmental Vitiligo",
                  "conditions": "Nonsegmental Vitiligo",
                  "description": "This is a Phase 2 clinical research study sponsored by Takeda Pharmaceuticals to test an investigational oral medication called zasocitinib for adults with nonsegmental vitiligo. The study is designed to be multicenter, meaning it will take place at various clinics and hospitals. It is a randomized, double-blind, placebo-controlled trial. This means participants will be randomly assigned (like a coin flip) to receive one of several different doses of zasocitinib or a placebo, which contains no active medicine. The double-blind design ensures that neither the participant nor the study doctor will know which treatment is being administered, which helps prevent bias in the results. The study will involve a screening period to determine eligibility, a treatment period, and a follow-up period.\n\nTo be eligible for this study, you must be an adult with a confirmed diagnosis of nonsegmental vitiligo. The study is looking for individuals whose vitiligo affects a certain amount of their body surface area and is considered stable or active. You may not be able to participate if you are pregnant or breastfeeding, have certain other medical conditions, or have recently used specific medications or therapies for vitiligo, including other JAK inhibitors or phototherapy. Before joining, the study team will explain all the details in an informed consent document, and you will have the opportunity to ask any questions to decide if participation is right for you.\n\nThe primary goal of this study is to evaluate how effective different doses of zasocitinib are at promoting skin repigmentation compared to a placebo. This will be measured by the study doctor using a standardized scoring system (Vitiligo Area Scoring Index, or VASI) that assesses changes in vitiligo on your face and body. The study will also assess the drug's safety and its impact on your quality of life through questionnaires. Participation requires regular visits to the study clinic for assessments, which will include physical exams, blood tests, medical photography to document skin changes, and completing surveys about your symptoms and well-being.",
                  "investigator_name": "Dr. Patrick Dennis",
                  "site_location": "New Orleans, LA",
                  "protocol_summary": "This is a Phase 2 clinical research study sponsored by Takeda Pharmaceuticals to test an investigational oral medication called zasocitinib for adults with nonsegmental vitiligo. The study is designed to be multicenter, meaning it will take place at various clinics and hospitals. It is a randomized, double-blind, placebo-controlled trial. This means participants will be randomly assigned (like a coin flip) to receive one of several different doses of zasocitinib or a placebo, which contains no active medicine. The double-blind design ensures that neither the participant nor the study doctor will know which treatment is being administered, which helps prevent bias in the results. The study will involve a screening period to determine eligibility, a treatment period, and a follow-up period.\n\nTo be eligible for this study, you must be an adult with a confirmed diagnosis of nonsegmental vitiligo. The study is looking for individuals whose vitiligo affects a certain amount of their body surface area and is considered stable or active. You may not be able to participate if you are pregnant or breastfeeding, have certain other medical conditions, or have recently used specific medications or therapies for vitiligo, including other JAK inhibitors or phototherapy. Before joining, the study team will explain all the details in an informed consent document, and you will have the opportunity to ask any questions to decide if participation is right for you.\n\nThe primary goal of this study is to evaluate how effective different doses of zasocitinib are at promoting skin repigmentation compared to a placebo. This will be measured by the study doctor using a standardized scoring system (Vitiligo Area Scoring Index, or VASI) that assesses changes in vitiligo on your face and body. The study will also assess the drug's safety and its impact on your quality of life through questionnaires. Participation requires regular visits to the study clinic for assessments, which will include physical exams, blood tests, medical photography to document skin changes, and completing surveys about your symptoms and well-being.",
                  "total_sites": 2,
                  "similarity_score": 0.7841763997694425
                },
                {
                  "id": 84,
                  "trial_name": "A Phase 1/2, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy and immunogenicity of an Acne mRNA vaccine candidate in participants with mild acne",
                  "conditions": "Acne Vulgaris",
                  "description": "This is a Phase 1/2, multi-center, randomized, double-blind, placebo-controlled study sponsored by Sanofi.  The study will be conducted in Singapore and potentially other countries.  This means that some participants will receive the acne vaccine and others will receive a placebo, and neither the participants nor the researchers will know who received which until the end of the study.  The study aims to evaluate the safety and effectiveness of two doses of an mRNA vaccine for mild acne. The duration of the study is not explicitly stated in the provided excerpt but includes a sentinel cohort followed by a main cohort and a long-term follow-up.\n\nThis study is looking for participants aged 18 to 45 years old with mild facial acne vulgaris.  To qualify, you must have an IGA score of mild (grade 2), 10-24 non-inflammatory lesions (like blackheads and whiteheads), and 5-19 inflammatory lesions (like papules and pustules), but no nodulocystic lesions.  Women must not be pregnant or breastfeeding and must use effective contraception or be post-menopausal/surgically sterile.  You cannot participate if you have certain medical conditions like immunodeficiency, allergies to vaccine components, history of myocarditis/pericarditis, chronic illness, bleeding disorders, or severe forms of acne.  Several acne treatments require a washout period before joining the study, ranging from 2 to 24 weeks depending on the treatment.  You should be able to attend all scheduled visits and comply with study procedures.\n\nParticipants will receive two administrations of either the acne mRNA vaccine or a placebo.  The study will measure the safety, effectiveness, and how the vaccine affects the immune system.  Safety will be assessed by monitoring for any side effects.  Effectiveness will be evaluated by measuring changes in acne lesions.  Immunogenicity will be assessed by measuring the body's immune response to the vaccine.  The visit schedule and specific procedures are not fully detailed in this summary, but will involve regular check-ups to assess your acne and monitor for any side effects.  The protocol mentions a sentinel cohort which will have a modified double-blind approach where site staff administering the vaccine and some sponsor staff will be unblinded.",
                  "investigator_name": "Dr. Deidre Hooper",
                  "site_location": "New Orleans, LA",
                  "protocol_summary": "This is a Phase 1/2, multi-center, randomized, double-blind, placebo-controlled study sponsored by Sanofi.  The study will be conducted in Singapore and potentially other countries.  This means that some participants will receive the acne vaccine and others will receive a placebo, and neither the participants nor the researchers will know who received which until the end of the study.  The study aims to evaluate the safety and effectiveness of two doses of an mRNA vaccine for mild acne. The duration of the study is not explicitly stated in the provided excerpt but includes a sentinel cohort followed by a main cohort and a long-term follow-up.\n\nThis study is looking for participants aged 18 to 45 years old with mild facial acne vulgaris.  To qualify, you must have an IGA score of mild (grade 2), 10-24 non-inflammatory lesions (like blackheads and whiteheads), and 5-19 inflammatory lesions (like papules and pustules), but no nodulocystic lesions.  Women must not be pregnant or breastfeeding and must use effective contraception or be post-menopausal/surgically sterile.  You cannot participate if you have certain medical conditions like immunodeficiency, allergies to vaccine components, history of myocarditis/pericarditis, chronic illness, bleeding disorders, or severe forms of acne.  Several acne treatments require a washout period before joining the study, ranging from 2 to 24 weeks depending on the treatment.  You should be able to attend all scheduled visits and comply with study procedures.\n\nParticipants will receive two administrations of either the acne mRNA vaccine or a placebo.  The study will measure the safety, effectiveness, and how the vaccine affects the immune system.  Safety will be assessed by monitoring for any side effects.  Effectiveness will be evaluated by measuring changes in acne lesions.  Immunogenicity will be assessed by measuring the body's immune response to the vaccine.  The visit schedule and specific procedures are not fully detailed in this summary, but will involve regular check-ups to assess your acne and monitor for any side effects.  The protocol mentions a sentinel cohort which will have a modified double-blind approach where site staff administering the vaccine and some sponsor staff will be unblinded.",
                  "total_sites": 1,
                  "similarity_score": 0.7720884592658063
                },
                {
                  "id": 90,
                  "trial_name": "A Phase I/II, randomized, placebo-controlled, multi-arm, dose-finding study to evaluate the safety, efficacy and immunogenicity of an Acne mRNA vaccine candidate in adults with moderate to severe acne 18 to 45 years of age",
                  "conditions": "Acne Vulgaris",
                  "description": "This is a Phase I/II study, meaning it's one of the first times this acne vaccine is being tested in humans.  The study is randomized, which means participants are assigned to different treatment groups by chance, like flipping a coin. Some participants will receive the vaccine, while others will receive a placebo (an inactive substance).  This helps researchers understand if the vaccine is truly effective.  The study is also 'double-blinded' (or 'modified double-blind' in some parts), meaning neither the participants nor the researchers know who is getting the vaccine or the placebo until the end of the study. Sanofi is sponsoring the study, which will be conducted at multiple sites in the US and potentially other countries. The study duration will depend on the dose and cohort, but will involve multiple visits over several months.\n\nThis study is looking for adults between 18 and 45 years old who have moderate to severe acne.  To qualify, you must have a certain number of pimples, blackheads, and whiteheads, as determined by a doctor.  You must be generally healthy and able to attend all scheduled study visits.  You cannot participate if you have certain medical conditions, like a weakened immune system, a history of heart inflammation (myocarditis or pericarditis), or certain skin conditions.  You also can't participate if you've recently received other vaccines, taken certain acne medications (like isotretinoin), or are pregnant or breastfeeding.  If you are eligible and choose to participate, you'll need to avoid other acne treatments during the study and follow the instructions provided by the study team.\n\nIn this study, participants will receive either the acne mRNA vaccine or a placebo by injection.  Researchers will be looking at how safe the vaccine is, how well it works to reduce acne, and how the body's immune system responds to it.  The main measurements will be the change in the number of acne lesions, how your skin looks overall, and the presence of antibodies against acne-causing bacteria in your blood.  You'll need to visit the study site several times over the course of the study for check-ups, assessments, and to receive the study injections. The exact schedule will depend on which part of the study you are in, but will likely involve visits over several months.  During these visits, doctors will examine your skin, take blood samples, and ask you about any side effects you may be experiencing.",
                  "investigator_name": "Dr. Deidre Hooper",
                  "site_location": "New Orleans, LA",
                  "protocol_summary": "This is a Phase I/II study, meaning it's one of the first times this acne vaccine is being tested in humans.  The study is randomized, which means participants are assigned to different treatment groups by chance, like flipping a coin. Some participants will receive the vaccine, while others will receive a placebo (an inactive substance).  This helps researchers understand if the vaccine is truly effective.  The study is also 'double-blinded' (or 'modified double-blind' in some parts), meaning neither the participants nor the researchers know who is getting the vaccine or the placebo until the end of the study. Sanofi is sponsoring the study, which will be conducted at multiple sites in the US and potentially other countries. The study duration will depend on the dose and cohort, but will involve multiple visits over several months.\n\nThis study is looking for adults between 18 and 45 years old who have moderate to severe acne.  To qualify, you must have a certain number of pimples, blackheads, and whiteheads, as determined by a doctor.  You must be generally healthy and able to attend all scheduled study visits.  You cannot participate if you have certain medical conditions, like a weakened immune system, a history of heart inflammation (myocarditis or pericarditis), or certain skin conditions.  You also can't participate if you've recently received other vaccines, taken certain acne medications (like isotretinoin), or are pregnant or breastfeeding.  If you are eligible and choose to participate, you'll need to avoid other acne treatments during the study and follow the instructions provided by the study team.\n\nIn this study, participants will receive either the acne mRNA vaccine or a placebo by injection.  Researchers will be looking at how safe the vaccine is, how well it works to reduce acne, and how the body's immune system responds to it.  The main measurements will be the change in the number of acne lesions, how your skin looks overall, and the presence of antibodies against acne-causing bacteria in your blood.  You'll need to visit the study site several times over the course of the study for check-ups, assessments, and to receive the study injections. The exact schedule will depend on which part of the study you are in, but will likely involve visits over several months.  During these visits, doctors will examine your skin, take blood samples, and ask you about any side effects you may be experiencing.",
                  "total_sites": 5,
                  "similarity_score": 0.7692959174605448
                }
              ],
              "semantic_search": true
            },
            "response_time": 20.02437400817871,
            "timestamp": "2025-12-15T21:58:22.460784"
          },
          {
            "user_message": "Yes, check my eligibility",
            "bot_response": "Great! I'll help you check your eligibility.\n\nI need to ask you a few questions about the psoriasis trial.\n\n**Question 1 of 5:** What is your age?",
            "metadata": {
              "session_id": "AUTO_TEST_random_003",
              "current_state": "prescreening_active",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "start_prescreening",
              "entities_collected": {
                "condition": null,
                "location": null,
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": true,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "start_prescreening",
                "parameters": {},
                "response_text": "Great, I can help with that. I'll ask a few simple questions to see if you might be a match for any of these Psoriasis trials. This is just a preliminary check, and the study team will make the final determination.\n\nTo start, could you please tell me your age?",
                "new_state": "prescreening_in_progress",
                "collect_entities": [
                  "age"
                ],
                "metadata": {
                  "reasoning": "The user has explicitly confirmed their interest in checking eligibility ('Yes, check my eligibility') after being shown a list of trials. The current state is 'trials_shown', which is the correct context for this request. The most appropriate action is to begin the prescreening process. The response acknowledges their request, sets expectations about the process, and asks the first common eligibility question (age) to move the conversation forward. The state is transitioned to 'prescreening_in_progress' to reflect the new conversational flow."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "prescreening_started": true,
              "trial_id": 109,
              "trial_name": "A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Zasocitinib in Participants with Nonsegmental Vitiligo",
              "current_question_index": 0,
              "total_questions": 5,
              "current_question": "What is your age?",
              "expected_answer_type": "number"
            },
            "response_time": 21.23750615119934,
            "timestamp": "2025-12-15T21:58:43.698846"
          },
          {
            "user_message": "53",
            "bot_response": "I had trouble processing your answer. There seems to be an issue with the prescreening system. Please try searching for trials again.",
            "metadata": {
              "session_id": "AUTO_TEST_random_003",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "continue_prescreening",
              "entities_collected": {
                "condition": null,
                "location": null,
                "age": 53,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "continue_prescreening",
                "parameters": {},
                "response_text": "Great, thanks for sharing. Next question: Are you currently using any topical, oral, or injectable medications for your psoriasis?",
                "new_state": "prescreening_active",
                "collect_entities": [
                  "boolean_answer"
                ],
                "metadata": {
                  "reasoning": "The user is in an active prescreening session and has just provided their age in response to a direct question. The correct action is to continue the prescreening process by asking the next logical eligibility question. The state remains 'prescreening_active' as the process is not yet complete."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "prescreening_error": "failed_to_process_answer",
              "error_details": "'coroutine' object has no attribute 'criterion_id'",
              "error_type": "AttributeError"
            },
            "response_time": 19.128833055496216,
            "timestamp": "2025-12-15T21:59:02.827997"
          }
        ],
        "final_state": "completed",
        "total_turns": 3,
        "total_questions_asked": 5,
        "errors": [
          {
            "type": "unexpected_state",
            "bot_response": "I had trouble processing your answer. There seems to be an issue with the prescreening system. Please try searching for trials again."
          }
        ]
      },
      "validation": {
        "passed": false,
        "overall_score": 70.0,
        "crash_prevention": {
          "passed": true,
          "score": 100.0,
          "error_count": 0,
          "errors": [],
          "failures": []
        },
        "eligibility_accuracy": {
          "passed": false,
          "score": 0.0,
          "reason": "Could not extract eligibility result",
          "failures": [
            {
              "type": "eligibility_logic_error",
              "reason": "No eligibility determination found in conversation",
              "likely_location": "core/prescreening/gemini_prescreening_manager.py:evaluate_eligibility()",
              "severity": "high"
            }
          ]
        },
        "conversation_quality": {
          "passed": true,
          "score": 100.0,
          "total_questions_asked": 5,
          "issues": [],
          "failures": []
        },
        "edge_case_handling": {
          "passed": true,
          "score": 100.0,
          "applicable": false,
          "failures": []
        },
        "performance": {
          "passed": false,
          "score": 40.0,
          "avg_response_time": 20.130237738291424,
          "max_response_time": 21.23750615119934,
          "status": "slow",
          "failures": [
            {
              "type": "performance_issue",
              "avg_response_time": 20.130237738291424,
              "max_response_time": 21.23750615119934,
              "severity": "low",
              "recommendation": "Investigate slow API responses or Gemini API delays"
            }
          ]
        },
        "failure_points": [
          {
            "type": "eligibility_logic_error",
            "reason": "No eligibility determination found in conversation",
            "likely_location": "core/prescreening/gemini_prescreening_manager.py:evaluate_eligibility()",
            "severity": "high"
          },
          {
            "type": "performance_issue",
            "avg_response_time": 20.130237738291424,
            "max_response_time": 21.23750615119934,
            "severity": "low",
            "recommendation": "Investigate slow API responses or Gemini API delays"
          }
        ],
        "recommendations": [
          "\u26a0\ufe0f HIGH: Review eligibility evaluation logic in gemini_prescreening_manager.py",
          "\u2139\ufe0f LOW: Slow response times. Optimize API calls or consider caching."
        ]
      },
      "timestamp": "2025-12-15T21:59:02.828649"
    },
    {
      "patient_id": "AUTO_TEST_edge_multimorbid_001",
      "patient_profile": {
        "patient_id": "AUTO_TEST_edge_multimorbid_001",
        "profile_type": "edge_case",
        "demographics": {
          "age": 69,
          "gender": "male",
          "location": "Baton Rouge, LA",
          "name": "Multi Condition Patient",
          "first_name": "Multi",
          "last_name": "Patient"
        },
        "medical_history": {
          "primary_condition": "Psoriasis",
          "conditions": [
            "Psoriasis",
            "Copd",
            "Gout",
            "Alzheimers",
            "Diabetes",
            "Hypertension"
          ],
          "medications": [
            "Insulin",
            "Febuxostat",
            "Symbicort",
            "Galantamine",
            "Biologics (Humira)"
          ],
          "duration_years": 10
        },
        "expected_behavior": {
          "should_find_trials": true,
          "likely_eligible": false,
          "expected_question_count_range": [
            5,
            10
          ],
          "edge_case_type": "multi_morbidity"
        }
      },
      "conversation_result": {
        "session_id": "AUTO_TEST_edge_multimorbid_001",
        "patient_id": "AUTO_TEST_edge_multimorbid_001",
        "conversation_log": [
          {
            "user_message": "Psoriasis trials in Baton Rouge, LA",
            "bot_response": "Great! I found 5 clinical trial(s) available in Baton Rouge:\n\n**Dr. Ira Thorla**\n  \u2022 Female Pattern Hair Loss (Androgenetic Alopecia) (1 trial)\n  \u2022 Hidradenitis Suppurativa (1 trial)\n  \u2022 Acne Vulgaris (1 trial)\n  \u2022 Atopic Dermatitis (1 trial)\n\n**Dr. Taylor Sanders**\n  \u2022 Nonsegmental Vitiligo (1 trial)\n\nWould you like to:\n1. Check your eligibility for any of these trials?\n2. Learn more about a specific condition?\n3. See trials in a different location?",
            "metadata": {
              "session_id": "AUTO_TEST_edge_multimorbid_001",
              "current_state": "trials_shown",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "search_trials",
              "entities_collected": {
                "condition": "Psoriasis",
                "location": "Baton Rouge",
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "search_trials",
                "parameters": {
                  "condition": "Psoriasis",
                  "location": "Baton Rouge"
                },
                "response_text": "Of course, I can help with that. I'm now searching for clinical trials for Psoriasis in Baton Rouge, LA. I'll have some results for you in just a moment.",
                "new_state": "trials_found",
                "collect_entities": [],
                "metadata": {
                  "reasoning": "The user has provided a new condition ('Psoriasis') and a new location ('Baton Rouge'), which constitutes a complete request to search for trials. This overrides the previous context. Since I have all the necessary information, the correct action is to perform the search."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "trials_found": 5,
              "condition": "Psoriasis",
              "location": "Baton Rouge",
              "trials_data": [
                {
                  "id": 14,
                  "trial_name": "Clinical Trial 250-13951-306",
                  "conditions": "Female Pattern Hair Loss (Androgenetic Alopecia)",
                  "description": null,
                  "investigator_name": "Dr. Ira Thorla",
                  "site_location": "Baton Rouge, LA",
                  "protocol_summary": "This clinical trial aims to investigate the effectiveness and safety of an oral medication called VDPHL01 for treating female pattern hair loss (androgenetic alopecia).  The study will evaluate two different dosing regimens of VDPHL01: twice daily and once daily.  It will compare these regimens against a placebo to see if the medication promotes hair growth and improves patient satisfaction with their hair.\n\nWomen aged 18-65 with mild to moderate hair loss, as measured by the Savin Scale, are eligible to participate.  Key inclusion criteria include good general health, adequate kidney and liver function, and a commitment to maintaining consistent hair care routines throughout the study.  Women who are pregnant, breastfeeding, have certain medical conditions (like uncontrolled blood pressure or a history of heart problems), or have recently used other hair growth treatments are excluded.\n\nThe study will last approximately 13 months and consist of two parts. Part A is a 6-month placebo-controlled period, where participants are randomly assigned to one of four groups: VDPHL01 twice daily, VDPHL01 once daily plus placebo, placebo twice daily, or placebo twice daily.  Part B is a 6-month treatment extension, where those initially receiving placebo will start taking VDPHL01 according to their initial group assignment, while those already on VDPHL01 will continue.  Participants will have regular clinic visits (approximately 11) for assessments including physical exams, blood and urine tests, electrocardiograms, photographs of the scalp, and questionnaires about their hair and quality of life. A small group of participants will also take part in interviews.  A final follow-up will occur one month after the treatment period ends.\n",
                  "total_sites": 2,
                  "similarity_score": 0.8174656906579815
                },
                {
                  "id": 109,
                  "trial_name": "A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Zasocitinib in Participants with Nonsegmental Vitiligo",
                  "conditions": "Nonsegmental Vitiligo",
                  "description": "This is a Phase 2 clinical research study sponsored by Takeda Pharmaceuticals to test an investigational oral medication called zasocitinib for adults with nonsegmental vitiligo. The study is designed to be multicenter, meaning it will take place at various clinics and hospitals. It is a randomized, double-blind, placebo-controlled trial. This means participants will be randomly assigned (like a coin flip) to receive one of several different doses of zasocitinib or a placebo, which contains no active medicine. The double-blind design ensures that neither the participant nor the study doctor will know which treatment is being administered, which helps prevent bias in the results. The study will involve a screening period to determine eligibility, a treatment period, and a follow-up period.\n\nTo be eligible for this study, you must be an adult with a confirmed diagnosis of nonsegmental vitiligo. The study is looking for individuals whose vitiligo affects a certain amount of their body surface area and is considered stable or active. You may not be able to participate if you are pregnant or breastfeeding, have certain other medical conditions, or have recently used specific medications or therapies for vitiligo, including other JAK inhibitors or phototherapy. Before joining, the study team will explain all the details in an informed consent document, and you will have the opportunity to ask any questions to decide if participation is right for you.\n\nThe primary goal of this study is to evaluate how effective different doses of zasocitinib are at promoting skin repigmentation compared to a placebo. This will be measured by the study doctor using a standardized scoring system (Vitiligo Area Scoring Index, or VASI) that assesses changes in vitiligo on your face and body. The study will also assess the drug's safety and its impact on your quality of life through questionnaires. Participation requires regular visits to the study clinic for assessments, which will include physical exams, blood tests, medical photography to document skin changes, and completing surveys about your symptoms and well-being.",
                  "investigator_name": "Dr. Taylor Sanders",
                  "site_location": "Baton Rouge, LA",
                  "protocol_summary": "This is a Phase 2 clinical research study sponsored by Takeda Pharmaceuticals to test an investigational oral medication called zasocitinib for adults with nonsegmental vitiligo. The study is designed to be multicenter, meaning it will take place at various clinics and hospitals. It is a randomized, double-blind, placebo-controlled trial. This means participants will be randomly assigned (like a coin flip) to receive one of several different doses of zasocitinib or a placebo, which contains no active medicine. The double-blind design ensures that neither the participant nor the study doctor will know which treatment is being administered, which helps prevent bias in the results. The study will involve a screening period to determine eligibility, a treatment period, and a follow-up period.\n\nTo be eligible for this study, you must be an adult with a confirmed diagnosis of nonsegmental vitiligo. The study is looking for individuals whose vitiligo affects a certain amount of their body surface area and is considered stable or active. You may not be able to participate if you are pregnant or breastfeeding, have certain other medical conditions, or have recently used specific medications or therapies for vitiligo, including other JAK inhibitors or phototherapy. Before joining, the study team will explain all the details in an informed consent document, and you will have the opportunity to ask any questions to decide if participation is right for you.\n\nThe primary goal of this study is to evaluate how effective different doses of zasocitinib are at promoting skin repigmentation compared to a placebo. This will be measured by the study doctor using a standardized scoring system (Vitiligo Area Scoring Index, or VASI) that assesses changes in vitiligo on your face and body. The study will also assess the drug's safety and its impact on your quality of life through questionnaires. Participation requires regular visits to the study clinic for assessments, which will include physical exams, blood tests, medical photography to document skin changes, and completing surveys about your symptoms and well-being.",
                  "total_sites": 2,
                  "similarity_score": 0.7841763997694425
                },
                {
                  "id": 80,
                  "trial_name": "A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa",
                  "conditions": "Hidradenitis Suppurativa",
                  "description": "This is a Phase 1, open-label (not blinded), single-group study sponsored by Incyte Corporation.  The study will be conducted at multiple locations (multicenter) and is designed to evaluate the safety and tolerability of ruxolitinib cream. The total study duration, including screening, treatment, and follow-up, could be up to approximately 24 weeks.\n\nThis study is for adults and adolescents aged 12 to 75 years who have been diagnosed with hidradenitis suppurativa (HS) for at least 6 months.  To be eligible, you must have at least 4 abscesses and inflammatory nodules affecting at least 3 different areas of your body, with a total treatment area greater than 20% of your body surface area.  You may not be eligible if you have certain other skin conditions or are taking specific medications. During the study, you will be asked to apply the study cream twice daily to all affected areas and attend regular visits for check-ups and assessments.\n\nIn this study, you will apply ruxolitinib 1.5% cream twice daily to all affected areas for 4 weeks.  Researchers will monitor your health through blood tests, physical exams, and by asking you about any side effects.  The main goals are to assess the safety and tolerability of the cream, including any side effects, and to measure how much of the drug gets into your bloodstream.  Secondary goals include evaluating the cream's effect on your HS lesions, pain, itching, and quality of life.  You will have regular visits during the 4-week treatment period and potentially for a longer extension period, followed by a final safety follow-up visit.",
                  "investigator_name": "Dr. Ira Thorla",
                  "site_location": "Baton Rouge, LA",
                  "protocol_summary": "This is a Phase 1, open-label (not blinded), single-group study sponsored by Incyte Corporation.  The study will be conducted at multiple locations (multicenter) and is designed to evaluate the safety and tolerability of ruxolitinib cream. The total study duration, including screening, treatment, and follow-up, could be up to approximately 24 weeks.\n\nThis study is for adults and adolescents aged 12 to 75 years who have been diagnosed with hidradenitis suppurativa (HS) for at least 6 months.  To be eligible, you must have at least 4 abscesses and inflammatory nodules affecting at least 3 different areas of your body, with a total treatment area greater than 20% of your body surface area.  You may not be eligible if you have certain other skin conditions or are taking specific medications. During the study, you will be asked to apply the study cream twice daily to all affected areas and attend regular visits for check-ups and assessments.\n\nIn this study, you will apply ruxolitinib 1.5% cream twice daily to all affected areas for 4 weeks.  Researchers will monitor your health through blood tests, physical exams, and by asking you about any side effects.  The main goals are to assess the safety and tolerability of the cream, including any side effects, and to measure how much of the drug gets into your bloodstream.  Secondary goals include evaluating the cream's effect on your HS lesions, pain, itching, and quality of life.  You will have regular visits during the 4-week treatment period and potentially for a longer extension period, followed by a final safety follow-up visit.",
                  "total_sites": 1,
                  "similarity_score": 0.7694749411748597
                }
              ],
              "semantic_search": true
            },
            "response_time": 19.37875008583069,
            "timestamp": "2025-12-15T21:58:21.791996"
          },
          {
            "user_message": "Yes, check my eligibility",
            "bot_response": "Great! I'll help you check your eligibility.\n\nI need to ask you a few questions about the psoriasis trial.\n\n**Question 1 of 4:** What is your age?",
            "metadata": {
              "session_id": "AUTO_TEST_edge_multimorbid_001",
              "current_state": "prescreening_active",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "start_prescreening",
              "entities_collected": {
                "condition": null,
                "location": null,
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": "yes",
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "start_prescreening",
                "parameters": {},
                "response_text": "Great! I can help with that. To see if you might be a match for any of these trials, I'll need to ask a few questions. This is just a preliminary check, and the final decision is always made by the study team.\n\nFirst, could you please tell me your age?",
                "new_state": "prescreening_in_progress",
                "collect_entities": [
                  "age"
                ],
                "metadata": {
                  "reasoning": "The user has explicitly agreed to an eligibility check after being shown a list of trials. The current state is 'trials_shown', making 'start_prescreening' the logical next step. The response confirms the user's request, explains the process, and asks the first common eligibility question (age) to begin the prescreening flow. The state is transitioned to 'prescreening_in_progress' to reflect this new phase."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "prescreening_started": true,
              "trial_id": 14,
              "trial_name": "Clinical Trial 250-13951-306",
              "current_question_index": 0,
              "total_questions": 4,
              "current_question": "What is your age?",
              "expected_answer_type": "number"
            },
            "response_time": 16.663821935653687,
            "timestamp": "2025-12-15T21:58:38.457978"
          },
          {
            "user_message": "69",
            "bot_response": "I had trouble processing your answer. There seems to be an issue with the prescreening system. Please try searching for trials again.",
            "metadata": {
              "session_id": "AUTO_TEST_edge_multimorbid_001",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "continue_prescreening",
              "entities_collected": {
                "condition": null,
                "location": null,
                "age": 69,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "continue_prescreening",
                "parameters": {},
                "response_text": "Okay, thank you for sharing that. Next question: Are you currently taking any medications or using any topical treatments for your psoriasis?",
                "new_state": "prescreening_active",
                "collect_entities": [
                  "medication",
                  "boolean_answer"
                ],
                "metadata": {
                  "reasoning": "The user is in an active prescreening state and has provided their age in response to a direct question. The correct action is to acknowledge their answer and proceed with the next question in the prescreening sequence to continue evaluating their potential eligibility. A question about current treatments is a logical next step for a psoriasis trial."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "prescreening_error": "failed_to_process_answer",
              "error_details": "'coroutine' object has no attribute 'criterion_id'",
              "error_type": "AttributeError"
            },
            "response_time": 17.203428745269775,
            "timestamp": "2025-12-15T21:58:55.662594"
          }
        ],
        "final_state": "completed",
        "total_turns": 3,
        "total_questions_asked": 4,
        "errors": [
          {
            "type": "unexpected_state",
            "bot_response": "I had trouble processing your answer. There seems to be an issue with the prescreening system. Please try searching for trials again."
          }
        ]
      },
      "validation": {
        "passed": false,
        "overall_score": 66.0,
        "crash_prevention": {
          "passed": true,
          "score": 100.0,
          "error_count": 0,
          "errors": [],
          "failures": []
        },
        "eligibility_accuracy": {
          "passed": false,
          "score": 0.0,
          "reason": "Could not extract eligibility result",
          "failures": [
            {
              "type": "eligibility_logic_error",
              "reason": "No eligibility determination found in conversation",
              "likely_location": "core/prescreening/gemini_prescreening_manager.py:evaluate_eligibility()",
              "severity": "high"
            }
          ]
        },
        "conversation_quality": {
          "passed": true,
          "score": 80.0,
          "total_questions_asked": 4,
          "issues": [
            "Too few questions asked (4, expected at least 5)"
          ],
          "failures": [
            {
              "type": "conversation_quality_issue",
              "issue": "Too few questions asked (4, expected at least 5)",
              "severity": "medium",
              "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
            }
          ]
        },
        "edge_case_handling": {
          "passed": true,
          "score": 100.0,
          "applicable": true,
          "edge_case_type": "multi_morbidity",
          "completed": true,
          "failures": []
        },
        "performance": {
          "passed": true,
          "score": 70.0,
          "avg_response_time": 17.748666922251385,
          "max_response_time": 19.37875008583069,
          "status": "acceptable",
          "failures": []
        },
        "failure_points": [
          {
            "type": "eligibility_logic_error",
            "reason": "No eligibility determination found in conversation",
            "likely_location": "core/prescreening/gemini_prescreening_manager.py:evaluate_eligibility()",
            "severity": "high"
          },
          {
            "type": "conversation_quality_issue",
            "issue": "Too few questions asked (4, expected at least 5)",
            "severity": "medium",
            "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
          }
        ],
        "recommendations": [
          "\u26a0\ufe0f HIGH: Review eligibility evaluation logic in gemini_prescreening_manager.py"
        ]
      },
      "timestamp": "2025-12-15T21:58:55.663414"
    },
    {
      "patient_id": "AUTO_TEST_random_001",
      "patient_profile": {
        "patient_id": "AUTO_TEST_random_001",
        "profile_type": "random",
        "demographics": {
          "age": 45,
          "gender": "male",
          "location": "Birmingham, AL",
          "name": "William Jones",
          "first_name": "William",
          "last_name": "Jones"
        },
        "medical_history": {
          "primary_condition": "Copd",
          "conditions": [
            "Copd"
          ],
          "medications": [
            "Albuterol",
            "Symbicort"
          ],
          "duration_years": 1
        },
        "expected_behavior": {
          "should_find_trials": true,
          "likely_eligible": true,
          "expected_question_count_range": [
            4,
            8
          ]
        }
      },
      "conversation_result": {
        "session_id": "AUTO_TEST_random_001",
        "patient_id": "AUTO_TEST_random_001",
        "conversation_log": [
          {
            "user_message": "Copd trials in Birmingham, AL",
            "bot_response": "I couldn't find any trials for Copd in Birmingham, AL at the moment. Would you like to try a different condition or location?",
            "metadata": {
              "session_id": "AUTO_TEST_random_001",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "search_trials",
              "entities_collected": {
                "condition": "Copd",
                "location": "Birmingham",
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "search_trials",
                "parameters": {
                  "condition": "Copd",
                  "location": "Birmingham, AL"
                },
                "response_text": "Of course, I can help with that. Let's look for clinical trials for COPD in Birmingham, Alabama. One moment while I search for you.",
                "new_state": "trials_shown",
                "collect_entities": [],
                "metadata": {
                  "reasoning": "The user has provided a new condition (COPD) and a new location (Birmingham, AL), indicating a clear intent to start a new search. This is a context switch from the previous search for Psoriasis. The `search_trials` action is the most direct way to fulfill this new request. The response acknowledges the change in topic, confirms the new search parameters, and informs the user that a search is being performed."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "no_trials_found": true,
              "condition": "Copd",
              "location": "Birmingham, AL"
            },
            "response_time": 18.310091018676758,
            "timestamp": "2025-12-15T21:59:21.139344"
          },
          {
            "user_message": "Yes, check my eligibility",
            "bot_response": "I need to know which specific trial you'd like to check eligibility for. Could you please search for trials first, or let me know what condition and location you're interested in?",
            "metadata": {
              "session_id": "AUTO_TEST_random_001",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "start_prescreening",
              "entities_collected": {
                "condition": null,
                "location": null,
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": true,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "start_prescreening",
                "parameters": {},
                "response_text": "Great, I can help with that. To check your eligibility, I'll ask a few questions based on the trial's criteria. This will help us see if it might be a good fit for you.\n\nFirst, could you please tell me your age?",
                "new_state": "prescreening_in_progress",
                "collect_entities": [
                  "age"
                ],
                "metadata": {
                  "reasoning": "The user has explicitly consented to an eligibility check ('Yes, check my eligibility'). The necessary information (condition and location) has already been collected in previous turns. Therefore, the correct next step is to initiate the prescreening process by asking the first eligibility question. Age is a common and non-intrusive starting point for prescreening. The state is updated to 'prescreening_in_progress' to reflect this new phase of the conversation."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "prescreening_error": "no_trial_id_found"
            },
            "response_time": 20.13993501663208,
            "timestamp": "2025-12-15T21:59:41.279805"
          },
          {
            "user_message": "Birmingham, AL",
            "bot_response": "I couldn't find any trials for Copd in Birmingham, AL at the moment. Would you like to try a different condition or location?",
            "metadata": {
              "session_id": "AUTO_TEST_random_001",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "search_trials",
              "entities_collected": {
                "condition": null,
                "location": "Birmingham, AL",
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "search_trials",
                "parameters": {
                  "condition": "Copd",
                  "location": "Birmingham, AL"
                },
                "response_text": "Great, thanks for confirming Birmingham, AL. I'm now searching for clinical trials for COPD in your area. Let me see what I can find for you.",
                "new_state": "search_results_displayed",
                "collect_entities": [],
                "metadata": {
                  "reasoning": "The user has provided a specific location ('Birmingham, AL') and we already have their condition ('Copd') from the conversation context. With both required pieces of information, the most appropriate action is to proceed with the clinical trial search. The response confirms the search parameters and informs the user of the next step."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "no_trials_found": true,
              "condition": "Copd",
              "location": "Birmingham, AL"
            },
            "response_time": 23.82343888282776,
            "timestamp": "2025-12-15T22:00:05.103710"
          },
          {
            "user_message": "Birmingham, AL",
            "bot_response": "I couldn't find any trials for Copd in Birmingham, AL at the moment. Would you like to try a different condition or location?",
            "metadata": {
              "session_id": "AUTO_TEST_random_001",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "search_trials",
              "entities_collected": {
                "condition": null,
                "location": "Birmingham, AL",
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "search_trials",
                "parameters": {
                  "condition": "Copd",
                  "location": "Birmingham, AL"
                },
                "response_text": "Great, thank you for confirming. I'm now searching for COPD clinical trials in or near Birmingham, AL. I'll have some results for you in just a moment.",
                "new_state": "trials_found",
                "collect_entities": [],
                "metadata": {
                  "reasoning": "The user has provided their location, and we already have their condition (COPD) from the conversation context. With both necessary pieces of information, the next logical and most helpful step is to execute the search for clinical trials. The response confirms the action, sets expectations, and transitions the state to reflect that search results will be presented next."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "no_trials_found": true,
              "condition": "Copd",
              "location": "Birmingham, AL"
            },
            "response_time": 20.35004496574402,
            "timestamp": "2025-12-15T22:00:25.454463"
          },
          {
            "user_message": "Birmingham, AL",
            "bot_response": "I couldn't find any trials for Copd in Birmingham, AL at the moment. Would you like to try a different condition or location?",
            "metadata": {
              "session_id": "AUTO_TEST_random_001",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "search_trials",
              "entities_collected": {
                "condition": null,
                "location": "Birmingham, AL",
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "search_trials",
                "parameters": {
                  "condition": "Copd",
                  "location": "Birmingham, AL"
                },
                "response_text": "Got it, Birmingham, AL. I'm searching for COPD clinical trials near you now. I'll share what I find in just a moment.",
                "new_state": "trials_found",
                "collect_entities": [],
                "metadata": {
                  "reasoning": "The user has provided both the necessary condition (COPD, from context) and location (Birmingham, AL). They repeated the location, indicating a clear and persistent intent to search. The most appropriate action is to execute the `search_trials` action with the available information to fulfill their request and move the conversation forward."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "no_trials_found": true,
              "condition": "Copd",
              "location": "Birmingham, AL"
            },
            "response_time": 15.442916870117188,
            "timestamp": "2025-12-15T22:00:40.898114"
          },
          {
            "user_message": "Birmingham, AL",
            "bot_response": "I couldn't find any trials for Copd in Birmingham, AL at the moment. Would you like to try a different condition or location?",
            "metadata": {
              "session_id": "AUTO_TEST_random_001",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "search_trials",
              "entities_collected": {
                "condition": null,
                "location": "Birmingham, AL",
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "search_trials",
                "parameters": {
                  "condition": "Copd",
                  "location": "Birmingham, AL"
                },
                "response_text": "Great, thank you for confirming Birmingham, AL. I have what I need now. I'm searching for COPD clinical trials in your area and will share the results with you in just a moment.",
                "new_state": "trials_found",
                "collect_entities": [],
                "metadata": {
                  "reasoning": "The user has provided both the necessary pieces of information: their condition (COPD) and location (Birmingham, AL). The user's message is a direct confirmation of their location, signaling they are ready for the search to proceed. The `search_trials` action is the most logical and helpful next step to move the conversation forward and meet the user's goal, especially after a long conversation history."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "no_trials_found": true,
              "condition": "Copd",
              "location": "Birmingham, AL"
            },
            "response_time": 17.508899927139282,
            "timestamp": "2025-12-15T22:00:58.408020"
          },
          {
            "user_message": "Birmingham, AL",
            "bot_response": "I couldn't find any trials for Copd in Birmingham, AL at the moment. Would you like to try a different condition or location?",
            "metadata": {
              "session_id": "AUTO_TEST_random_001",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "search_trials",
              "entities_collected": {
                "condition": null,
                "location": "Birmingham, AL",
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "search_trials",
                "parameters": {
                  "condition": "Copd",
                  "location": "Birmingham, AL"
                },
                "response_text": "Got it, thanks for confirming Birmingham, AL. I'm looking for COPD clinical trials in that area for you now. This should just take a moment.",
                "new_state": "trials_found",
                "collect_entities": [],
                "metadata": {
                  "reasoning": "The user has provided and now re-confirmed both the necessary pieces of information: their condition (COPD) and their location (Birmingham, AL). The most logical and helpful next step is to execute the search for clinical trials based on this confirmed information. The response acknowledges their confirmation, clearly states the action being taken, and sets a brief expectation for the search."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "no_trials_found": true,
              "condition": "Copd",
              "location": "Birmingham, AL"
            },
            "response_time": 15.246609926223755,
            "timestamp": "2025-12-15T22:01:13.655593"
          },
          {
            "user_message": "Birmingham, AL",
            "bot_response": "Thanks for confirming your location in Birmingham, AL. I understand you're looking for trials there. I've double-checked, and it seems there aren't any active trials for COPD listed right in Birmingham at the moment. However, sometimes the best match is in a nearby city. Would you be open to me expanding the search to a 50-mile radius to see if there's anything close by?",
            "metadata": {
              "session_id": "AUTO_TEST_random_001",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "general_response",
              "entities_collected": {
                "condition": null,
                "location": "Birmingham, AL",
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "general_response",
                "parameters": {},
                "response_text": "Thanks for confirming your location in Birmingham, AL. I understand you're looking for trials there. I've double-checked, and it seems there aren't any active trials for COPD listed right in Birmingham at the moment. However, sometimes the best match is in a nearby city. Would you be open to me expanding the search to a 50-mile radius to see if there's anything close by?",
                "new_state": "awaiting_radius_confirmation",
                "collect_entities": [],
                "metadata": {
                  "reasoning": "The user has repeated their location after a previous search likely found no results. Simply running the same search again would be unhelpful and create a frustrating loop. The best course of action is to acknowledge their confirmation, gently restate that there are no trials in that specific city, and then proactively offer a helpful alternative, such as expanding the search radius. This demonstrates empathy and provides a constructive path forward."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "general_response": true
            },
            "response_time": 17.740989923477173,
            "timestamp": "2025-12-15T22:01:31.397297"
          },
          {
            "user_message": "Birmingham, AL",
            "bot_response": "I understand you're looking for trials specifically in Birmingham, AL. I've double-checked, and unfortunately, I'm still not finding any active clinical trials for COPD right in that area in my database. I know how frustrating that can be when you're looking for options close to home.\n\nWould you like me to save this search and notify you if a new trial for COPD opens up near Birmingham in the future?",
            "metadata": {
              "session_id": "AUTO_TEST_random_001",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "general_response",
              "entities_collected": {
                "condition": null,
                "location": "Birmingham, AL",
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "general_response",
                "parameters": {},
                "response_text": "I understand you're looking for trials specifically in Birmingham, AL. I've double-checked, and unfortunately, I'm still not finding any active clinical trials for COPD right in that area in my database. I know how frustrating that can be when you're looking for options close to home.\n\nWould you like me to save this search and notify you if a new trial for COPD opens up near Birmingham in the future?",
                "new_state": "offered_notification",
                "collect_entities": [],
                "metadata": {
                  "reasoning": "The user has repeated their location after being informed that no trials were found, indicating a strong preference for that specific area and an implicit rejection of a broader search. Performing another search would be redundant and unhelpful. The best action is to acknowledge their preference, gently reiterate the lack of results, and offer a different, constructive path forward. Offering to set up a notification for future trials is a helpful, proactive alternative that respects their location constraint while keeping them engaged and supported."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "general_response": true
            },
            "response_time": 24.73931574821472,
            "timestamp": "2025-12-15T22:01:56.137466"
          },
          {
            "user_message": "I'm not sure, can you clarify?",
            "bot_response": "Of course, I'm happy to clarify. Based on our conversation, I understand you're looking for clinical trials for COPD in the Birmingham, Alabama area. My next step would be to search for trials based on that information. Would you like me to go ahead and do that now?",
            "metadata": {
              "session_id": "AUTO_TEST_random_001",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "clarify_request",
              "entities_collected": {
                "condition": null,
                "location": null,
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "clarify_request",
                "parameters": {},
                "response_text": "Of course, I'm happy to clarify. Based on our conversation, I understand you're looking for clinical trials for COPD in the Birmingham, Alabama area. My next step would be to search for trials based on that information. Would you like me to go ahead and do that now?",
                "new_state": "ready_to_search",
                "collect_entities": [],
                "metadata": {
                  "reasoning": "The user is explicitly asking for clarification ('can you clarify?'). The current context shows we have both the condition (COPD) and location (Birmingham, AL) needed to search for trials. The best action is to clarify the current situation and the logical next step, which is to perform the search. The response re-states the gathered information, proposes the search, and asks for confirmation to proceed, directly addressing the user's uncertainty. The state is updated to 'ready_to_search' as we now have all the necessary information and are awaiting the user's confirmation."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "general_response": true
            },
            "response_time": 20.827279090881348,
            "timestamp": "2025-12-15T22:02:16.965420"
          },
          {
            "user_message": "I'm not sure, can you clarify?",
            "bot_response": "Of course, I'm happy to clarify. So far, you've shared that you're looking for clinical trials for COPD and are located in Birmingham, AL. My next step would be to use this information to search for trials that might be a good fit for you. Would you like me to go ahead and do that?",
            "metadata": {
              "session_id": "AUTO_TEST_random_001",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "general_response",
              "entities_collected": {
                "condition": null,
                "location": null,
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "general_response",
                "parameters": {},
                "response_text": "Of course, I'm happy to clarify. So far, you've shared that you're looking for clinical trials for COPD and are located in Birmingham, AL. My next step would be to use this information to search for trials that might be a good fit for you. Would you like me to go ahead and do that?",
                "new_state": "awaiting_search_confirmation",
                "collect_entities": [
                  "boolean_answer"
                ],
                "metadata": {
                  "reasoning": "The user is expressing uncertainty and asking for clarification. The best course of action is to provide a `general_response` that summarizes the current context (we have their condition and location) and clearly states the proposed next step (searching for trials). This directly addresses their confusion and empowers them to confirm before proceeding. The state is updated to `awaiting_search_confirmation` to reflect that we are now waiting for their go-ahead to search."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "general_response": true
            },
            "response_time": 22.128560066223145,
            "timestamp": "2025-12-15T22:02:39.094321"
          },
          {
            "user_message": "I'm not sure, can you clarify?",
            "bot_response": "Of course, I'm happy to clarify. Based on our conversation, I have that you're interested in clinical trials for COPD and are located in Birmingham, AL. My suggestion was to use this information to search for trials that might be a good fit for you. Would you like me to go ahead and do that?",
            "metadata": {
              "session_id": "AUTO_TEST_random_001",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "general_response",
              "entities_collected": {
                "condition": null,
                "location": null,
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "general_response",
                "parameters": {},
                "response_text": "Of course, I'm happy to clarify. Based on our conversation, I have that you're interested in clinical trials for COPD and are located in Birmingham, AL. My suggestion was to use this information to search for trials that might be a good fit for you. Would you like me to go ahead and do that?",
                "new_state": "initial",
                "collect_entities": [],
                "metadata": {
                  "reasoning": "The user is explicitly asking for clarification on the proposed next step. The most helpful action is to re-explain the plan in simple terms and ask for their confirmation to proceed. Since we have both the condition (COPD) and location (Birmingham, AL), the logical next step is to search for trials. This response clarifies that intention and gives the user control over the conversation's direction."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "general_response": true
            },
            "response_time": 18.979183673858643,
            "timestamp": "2025-12-15T22:02:58.073896"
          },
          {
            "user_message": "I'm not sure, can you clarify?",
            "bot_response": "My apologies for any confusion. I want to make sure I'm providing the clearest information possible. To help me understand, could you please tell me a bit more about what you'd like me to clarify? For example, are you unsure about the next step, or how the trial search process works? I'm here to help.",
            "metadata": {
              "session_id": "AUTO_TEST_random_001",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "clarify_request",
              "entities_collected": {
                "condition": null,
                "location": null,
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "clarify_request",
                "parameters": {},
                "response_text": "My apologies for any confusion. I want to make sure I'm providing the clearest information possible. To help me understand, could you please tell me a bit more about what you'd like me to clarify? For example, are you unsure about the next step, or how the trial search process works? I'm here to help.",
                "new_state": null,
                "collect_entities": [],
                "metadata": {
                  "reasoning": "The user has asked for clarification for the fourth time, indicating they are stuck in a conversational loop and are confused about the previous turn. We already have the necessary information (condition and location) to search for trials, but proceeding would ignore the user's direct request and likely increase their frustration. The best action is to break the loop by explicitly asking the user what specific point is unclear. This empathetic approach directly addresses their request and aims to get the conversation back on track toward their goal."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "general_response": true
            },
            "response_time": 22.06090497970581,
            "timestamp": "2025-12-15T22:03:20.135626"
          },
          {
            "user_message": "I'm not sure, can you clarify?",
            "bot_response": "My apologies if I've caused any confusion. It sounds like we might be going in circles, and I want to make sure I'm being as helpful as possible. \n\nSo far, I know you're looking for clinical trials for COPD in the Birmingham, AL area. \n\nWould you like me to go ahead and search for those trials now? Or was there something else you had a question about first?",
            "metadata": {
              "session_id": "AUTO_TEST_random_001",
              "current_state": "initial",
              "handler_used": "GeminiConversationManager",
              "processing_method": "gemini_conversation_manager",
              "action_type": "clarify_request",
              "entities_collected": {
                "condition": null,
                "location": null,
                "age": null,
                "medication": null,
                "number": null,
                "trial_name": null,
                "boolean_answer": null,
                "confidence_scores": {}
              },
              "conversation_action": {
                "action_type": "clarify_request",
                "parameters": {},
                "response_text": "My apologies if I've caused any confusion. It sounds like we might be going in circles, and I want to make sure I'm being as helpful as possible. \n\nSo far, I know you're looking for clinical trials for COPD in the Birmingham, AL area. \n\nWould you like me to go ahead and search for those trials now? Or was there something else you had a question about first?",
                "new_state": "initial",
                "collect_entities": [],
                "metadata": {
                  "reasoning": "The user has sent a generic clarification request for the fourth time after a long conversation, indicating they are stuck in a conversational loop. The best course of action is to break this loop by taking initiative. The response acknowledges the confusion, empathetically resets the context by summarizing the user's goal (finding COPD trials in Birmingham), and provides a clear, binary choice to move forward: either search for trials or ask a different question. This proactive approach is more effective than simply asking 'What can I clarify?' again, as it guides the user toward a productive next step."
                }
              },
              "user_analysis": {
                "sentiment": "neutral",
                "communication_style": "standard",
                "complexity_preference": "moderate"
              },
              "general_response": true
            },
            "response_time": 23.441776037216187,
            "timestamp": "2025-12-15T22:03:43.578182"
          }
        ],
        "final_state": "failed",
        "total_turns": 14,
        "total_questions_asked": 0,
        "errors": [
          {
            "type": "timeout",
            "message": "I'm not sure, can you clarify?",
            "response_time": 30.823654890060425
          },
          {
            "type": "conversation_failure",
            "error": "",
            "state": "prescreening_active",
            "timestamp": "2025-12-15T22:04:14.402740"
          }
        ]
      },
      "validation": {
        "passed": false,
        "overall_score": 11.0,
        "crash_prevention": {
          "passed": false,
          "score": 0.0,
          "error_count": 2,
          "errors": [
            {
              "type": "timeout",
              "message": "I'm not sure, can you clarify?",
              "response_time": 30.823654890060425
            },
            {
              "type": "conversation_failure",
              "error": "",
              "state": "prescreening_active",
              "timestamp": "2025-12-15T22:04:14.402740"
            }
          ],
          "failures": [
            {
              "type": "crash",
              "error_type": "timeout",
              "error_message": "Unknown error",
              "likely_location": "aiohttp timeout in conversation_simulator.py or slow Gemini API response",
              "severity": "critical"
            },
            {
              "type": "crash",
              "error_type": "conversation_failure",
              "error_message": "",
              "likely_location": "Unknown - check full error trace",
              "severity": "critical"
            }
          ]
        },
        "eligibility_accuracy": {
          "passed": false,
          "score": 0.0,
          "reason": "Prescreening did not complete",
          "failures": [
            {
              "type": "eligibility_logic_error",
              "reason": "Prescreening flow did not complete",
              "final_state": "failed",
              "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py",
              "severity": "high"
            }
          ]
        },
        "conversation_quality": {
          "passed": false,
          "score": 5.0,
          "total_questions_asked": 0,
          "issues": [
            "Too few questions asked (0, expected at least 4)",
            "Repeated question: I couldn't find any trials for Copd in Birmingham,...",
            "Repeated question: I couldn't find any trials for Copd in Birmingham,...",
            "Repeated question: I couldn't find any trials for Copd in Birmingham,...",
            "Repeated question: I couldn't find any trials for Copd in Birmingham,...",
            "Repeated question: I couldn't find any trials for Copd in Birmingham,..."
          ],
          "failures": [
            {
              "type": "conversation_quality_issue",
              "issue": "Too few questions asked (0, expected at least 4)",
              "severity": "medium",
              "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
            },
            {
              "type": "conversation_quality_issue",
              "issue": "Repeated question: I couldn't find any trials for Copd in Birmingham,...",
              "severity": "medium",
              "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
            },
            {
              "type": "conversation_quality_issue",
              "issue": "Repeated question: I couldn't find any trials for Copd in Birmingham,...",
              "severity": "medium",
              "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
            },
            {
              "type": "conversation_quality_issue",
              "issue": "Repeated question: I couldn't find any trials for Copd in Birmingham,...",
              "severity": "medium",
              "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
            },
            {
              "type": "conversation_quality_issue",
              "issue": "Repeated question: I couldn't find any trials for Copd in Birmingham,...",
              "severity": "medium",
              "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
            },
            {
              "type": "conversation_quality_issue",
              "issue": "Repeated question: I couldn't find any trials for Copd in Birmingham,...",
              "severity": "medium",
              "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
            }
          ]
        },
        "edge_case_handling": {
          "passed": true,
          "score": 100.0,
          "applicable": false,
          "failures": []
        },
        "performance": {
          "passed": false,
          "score": 40.0,
          "avg_response_time": 20.052853294781276,
          "max_response_time": 24.73931574821472,
          "status": "slow",
          "failures": [
            {
              "type": "performance_issue",
              "avg_response_time": 20.052853294781276,
              "max_response_time": 24.73931574821472,
              "severity": "low",
              "recommendation": "Investigate slow API responses or Gemini API delays"
            }
          ]
        },
        "failure_points": [
          {
            "type": "crash",
            "error_type": "timeout",
            "error_message": "Unknown error",
            "likely_location": "aiohttp timeout in conversation_simulator.py or slow Gemini API response",
            "severity": "critical"
          },
          {
            "type": "crash",
            "error_type": "conversation_failure",
            "error_message": "",
            "likely_location": "Unknown - check full error trace",
            "severity": "critical"
          },
          {
            "type": "eligibility_logic_error",
            "reason": "Prescreening flow did not complete",
            "final_state": "failed",
            "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py",
            "severity": "high"
          },
          {
            "type": "conversation_quality_issue",
            "issue": "Too few questions asked (0, expected at least 4)",
            "severity": "medium",
            "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
          },
          {
            "type": "conversation_quality_issue",
            "issue": "Repeated question: I couldn't find any trials for Copd in Birmingham,...",
            "severity": "medium",
            "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
          },
          {
            "type": "conversation_quality_issue",
            "issue": "Repeated question: I couldn't find any trials for Copd in Birmingham,...",
            "severity": "medium",
            "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
          },
          {
            "type": "conversation_quality_issue",
            "issue": "Repeated question: I couldn't find any trials for Copd in Birmingham,...",
            "severity": "medium",
            "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
          },
          {
            "type": "conversation_quality_issue",
            "issue": "Repeated question: I couldn't find any trials for Copd in Birmingham,...",
            "severity": "medium",
            "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
          },
          {
            "type": "conversation_quality_issue",
            "issue": "Repeated question: I couldn't find any trials for Copd in Birmingham,...",
            "severity": "medium",
            "likely_location": "core/conversation/gemini_conversation_manager.py or core/prescreening/gemini_prescreening_manager.py"
          },
          {
            "type": "performance_issue",
            "avg_response_time": 20.052853294781276,
            "max_response_time": 24.73931574821472,
            "severity": "low",
            "recommendation": "Investigate slow API responses or Gemini API delays"
          }
        ],
        "recommendations": [
          "\ud83d\udea8 CRITICAL: Fix crashes and exceptions. Review error logs and add error handling.",
          "\u26a0\ufe0f HIGH: Review eligibility evaluation logic in gemini_prescreening_manager.py",
          "\u26a0\ufe0f MEDIUM: Major conversation quality issues. Review question generation and response handling.",
          "\u2139\ufe0f LOW: Slow response times. Optimize API calls or consider caching."
        ]
      },
      "timestamp": "2025-12-15T22:04:14.403112"
    }
  ]
}